SEARCH
検索詳細
松岡 広大学院医学研究科 医科学専攻教授
研究活動情報
■ 論文- Natural killer (NK)/T-cell lymphomas are a highly aggressive lymphoma subtype common in East Asia and Latin America. To develop a therapeutic monoclonal antibody (mAb) against it, BALB/c mice were alternately immunized with two vigorous NK lymphoma cell lines. After hybridization, culture supernatants of the hybridoma clones were added to a third NK lymphoma cell line not used for immunization, and the antibodies were screened for direct cytolytic activity. Results showed that the newly established mAb, named mAb ANAP, induced immediate cell death against NK lymphoma cells in a cytoskeleton-dependent manner, which was also complement-, antibody-dependent cell-mediated cytotoxicity-, and caspase-independent, forming large pores on target cell surface within 20 min; mAb ANAP did not injure normal cells and could bind to the ITGA4 (CD49d). Contrary to existing anti-ITGA4 antibodies, which did not exhibit any destructive activity against NK lymphoma, ANAP antibody has promising potential as a therapeutic agent for NK lymphoma.2025年12月, Scientific reports, 15(1) (1), 45655 - 45655, 英語, 国際誌研究論文（学術雑誌）
- Abstract Background In patients diagnosed with AML, the implementation of leukemia gene testing in accordance with the ELN 2022 guidelines is of paramount importance for the stratification of prognoses, thereby facilitating the determination of optimal treatment strategies. Presently, comprehensive NGS-based methods are extensively employed for these classifications; however, implementing them globally, including in Japan, is constrained by several factors in daily clinical practice, such as cost per sample, turn-around time, and technical hurdles in quality control. Aims The objective of this study was to develop a cost-effective screening system capable of simultaneously screening multiple genes necessary for prognostic stratification of known targets. In the previous report, we selected three specific mutations: NPM1 mutations, FLT3-ITD mutations, and in-frame indel mutations in the bZIP domain of the CEBPA and developed assay panel. Since these mutations can be detected based on the length of DNA fragments, we adopted a multiplex fragment analysis method using a capillary electrophoresis sequencer (CES), which is cost-effective, highly sensitive and competent for various length of fragments. Methods We assessed the clinical performance of our assay panel measured 53 de novo AML patient samples (median age, 66 years; 36 males and 18 females). We employed the Sanger sequencing method as a control method. We detected the presence or absence of each mutation in the patient samples and calculated the percentage of agreement with the Sanger sequencing analysis. Clinical samples were obtained from Bioresource Center, Kobe University Hospital in accordance with the Declaration of Helsinki and under an approved Kobe University institutional research protocol (B240242). Results We confirmed 100% accuracy in comparison with the Sanger sequencing, which is the control method. The breakdown of mutations contained in clinical samples was as follows: 12 samples with NPM1 mutations, 11 samples with FLT3-ITD mutations, and 1 sample with in-frame indel mutations in the bZIP domain of the CEBPA, although the number of positive results includes duplicate calculations for samples containing multiple genetic mutations. For samples with a low mutation allelic ratio, the presence of mutations was confirmed, but they were below the sensitivity of the Sanger sequencing and could not be sequenced. Also, it was found that some FLT3-ITD mutation-positive samples contained ITDs of multiple sizes, with up to four different sizes (63, 69, 84, and 175 bp) of ITDs identified. Discussion In our previous report, it was demonstrated that the assay panel achieved 100% accuracy in agreement with Sanger sequencing when using simulated samples created by mixing synthetic genes with healthy human peripheral blood mononuclear cells, and detected mutations at a rate of 2.9%. In this clinical evaluation, utilizing real patient's cells, the method exhibited substantial agreement with the control method, thereby reinforcing its efficacy. It is noteworthy that even low-frequency variants were effectively identified. This case suggests that the assay panel may be useful for classifying the disease appropriately and determining treatment strategies in MDS with a tumor content of less than 20%, based on the 5th edition of the WHO classification. Furthermore, the test demonstrated an adequate capability to detect samples with multiple FLT3-ITDs of multiple sizes. Due to the inherent characteristics of NGS technology, the detection and annotation of these types of mutation remain intricate, and the design of primers that are specific to each mutation in qPCR is an arduous task. Conclusion The three-gene assay panel using our developed fragment analysis system in CES was able to detect the mutations of three key genes that can be used for minimum decision-making to perform prognosis stratification of de novo AML in accordance with current ELN guidelines in a manner that is rapid, highly sensitive, and cost-effective in comparison to NGS. Additionally, it can handle a wide range of mutation patterns without customization, a feature that distinguishes it from qPCR. We consider that this will enable rapid risk stratification prior to standard treatment to be provided to clinical settings in diverse regions around the world.American Society of Hematology, 2025年11月, Blood, 146(Supplement 1) (Supplement 1), 7854 - 7854研究論文（学術雑誌）
- (一社)日本医療検査科学会, 2025年08月, 医療検査と自動化, 50(4) (4), 281 - 281, 日本語
- (一社)日本医療検査科学会, 2025年08月, 医療検査と自動化, 50(4) (4), 283 - 283, 日本語
- (一社)日本臨床検査医学会, 2025年07月, 日本臨床検査医学会誌, 73(補冊) (補冊), 206 - 206, 日本語Fib4 indexは関節リウマチ患者においてMTX継続率を予想する
- Asciminib is a first-in-class BCR::ABL1 inhibitor that Specifically Targets the ABL1 Myristoyl Pocket (STAMP). It is approved worldwide and in Japan for chronic myeloid leukemia in chronic phase (CML-CP) with resistance or intolerance to previous tyrosine kinase inhibitor (TKI) therapy. In the Phase 3 ASCEMBL study, patients with CML-CP who received ≥ 2 prior ATP-competitive TKIs were randomized (2:1) to asciminib 40 mg twice-daily or bosutinib 500 mg once-daily. Here, we report the 96-week results of the subgroup analysis of Japanese patients (asciminib, n = 13; bosutinib, n = 3) in the ASCEMBL study. The MMR rate at Week 96 was 46.2% in asciminib-treated patients, increasing from Weeks 24 and 48. Patients who achieved MMR at Week 24 remained in MMR up to the Week 96 cutoff. While a high proportion of patients treated with asciminib remained on treatment at cutoff, none randomized to bosutinib were on treatment at Week 96. Despite the longer duration of exposure to asciminib, its safety and tolerability continued to be favorable with no new or worsening safety findings. Overall, the efficacy and safety outcomes in the Japanese subgroup were comparable with the ASCEMBL global study population, which supports the use of asciminib in Japanese patients with previously treated CML-CP.2024年09月, International journal of hematology, 120(3) (3), 305 - 313, 英語, 国内誌研究論文（学術雑誌）
- Sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is a life-threatening complication of hematopoietic stem cell transplantation (HSCT). Early diagnosis of SOS/VOD is associated with improved clinical outcomes. In 2023, the refined European Society for Blood and Marrow Transplantation diagnostic and severity criteria (refined EBMT criteria 2023) have been advocated. The revision has introduced new diagnostic categories, namely; probable, clinical, and proven SOS/VOD. In addition, the Sequential Organ Failure Assessment (SOFA) score has been newly incorporated into the SOS/VOD severity grading. We performed a retrospective analysis to evaluate the utility of these criteria. We analyzed 161 cases who underwent allogeneic HSCT. We identified 53 probable, 23 clinical, and 4 proven SOS/VOD cases. Probable SOS/VOD was diagnosed a median of 5.0 days earlier (interquartile range: 2-13 days, P < 0.001) than that of clinical SOS/VOD. The development of probable SOS/VOD alone was associated with a significantly inferior survival proportion compared to non-SOS/VOD (100-day survival, 86.2% vs. 94.3%, P = 0.012). The SOFA score contributed to the prediction of prognosis. Consequently, the refined EBMT criteria 2023 demonstrated the utility of SOS/VOD diagnosis and severity grading. Further investigations and improvements in these criteria are warranted.2024年04月, Bone marrow transplantation, 59(4) (4), 518 - 525, 英語, 国際誌研究論文（学術雑誌）
- Tumor-associated macrophages (TAMs) are abundant in the tumor microenvironment and are considered potential targets for cancer immunotherapy. To examine the antitumor effects of agents targeting human TAMs in vivo, we here established preclinical tumor xenograft models based on immunodeficient mice that express multiple human cytokines and have been reconstituted with a human immune system by transplantation of human CD34+ hematopoietic stem and progenitor cells (HIS-MITRG mice). HIS-MITRG mice supported the growth of both human cell line (Raji)– and patient-derived B cell lymphoma as well as the infiltration of human macrophages into their tumors. We examined the potential antitumor action of an antibody to human SIRPα (SE12C3) that inhibits the interaction of CD47 on tumor cells with SIRPα on human macrophages and thereby promotes Fcγ receptor–mediated phagocytosis of the former cells by the latter. Treatment with the combination of rituximab (antibody to human CD20) and SE12C3 inhibited Raji tumor growth in HIS-MITRG mice to a markedly greater extent than did rituximab monotherapy. This enhanced antitumor effect was dependent on human macrophages and attributable to enhanced rituximab-dependent phagocytosis of lymphoma cells by human macrophages. Treatment with rituximab and SE12C3 also induced reprogramming of human TAMs toward a proinflammatory phenotype. Furthermore, the combination treatment essentially prevented the growth of patient-derived diffuse large B cell lymphoma in HIS-MITRG mice. Our findings thus support the study of HIS-MITRG mice as a model for the preclinical evaluation in vivo of potential therapeutics, such as antibodies to human SIRPα, that target human TAMs.Frontiers Media SA, 2023年12月, Frontiers in Immunology, 14, 1294814 - 1294814, 英語, 国際誌研究論文（学術雑誌）
- Objective High-dose chemotherapy with autologous hematopoietic stem cell transplantation (auto-HSCT) is an effective treatment option for relapsed and refractory aggressive malignant lymphoma. However, patients frequently experience treatment-induced gastrointestinal symptoms. Synbiotics, including live microorganisms and nondigestible food ingredients, reportedly ameliorate chemotherapy-induced mucosal damage. In this study, we assessed the efficacy and safety of synbiotics in patients undergoing auto-HSCT. Methods This randomized, double-blinded study included patients with malignant lymphoma eligible for auto-HSCT. The patients were randomly assigned to either a synbiotic group receiving Bifidobacterium longum (BB536) and guar gum or a placebo group receiving a placebo containing dextrin. The supplements were administered twice daily from the start of conditioning chemotherapy up to 28 days after auto-HSCT. The primary endpoint was the duration of total parenteral nutrition (TPN). Results In total, 12 patients were included and randomized. The median duration of TPN was 15 (range, 12-33) days in the synbiotic group and 17.5 (range, 0-32) days in the placebo group. The median duration of grade ≥3 diarrhea was shorter in the synbiotic group than in then placebo group (2.5 vs. 6.5 days), as was the duration of hospital stay (31.5 vs. 43 days). The oral intake and quality of life regarding diarrhea and anorexia improved in the synbiotic group after engraftment. Synbiotic infections, including bacteremia, were not observed. Conclusion Synbiotics may reduce gastrointestinal toxicity, thereby reducing nutritional problems and improving the quality of life of patients undergoing auto-HSCT, without severe adverse events.2023年10月, Internal medicine (Tokyo, Japan), 62(20) (20), 2949 - 2958, 英語, 国内誌研究論文（学術雑誌）
- BACKGROUND: We previously demonstrated that CD34 + cell transplantation in animals healed intractable fractures via osteogenesis and vasculogenesis; we also demonstrated the safety and efficacy of this cell therapy in an earlier phase I/II clinical trial conducted on seven patients with fracture nonunion. Herein, we present the results of a phase III clinical trial conducted to confirm the results of the previous phase studies using a larger cohort of patients. METHODS: CD34 + cells were mobilized via administration of granulocyte colony-stimulating factor, harvested using leukapheresis, and isolated using magnetic cell sorting. Autologous CD34 + cells were transplanted in 15 patients with tibia nonunion and 10 patients with femur nonunion, who were followed up for 52 weeks post transplantation. The main outcome was a reduction in time to heal the tibia in nonunion patients compared with that in historical control patients. We calculated the required number of patients as 15 based on the results of the phase I/II study. An independent data monitoring committee performed the radiographic assessments. Adverse events and medical device failures were recorded. RESULTS: All fractures healed during the study period. The time to radiological fracture healing was 2.8 times shorter in patients with CD34 + cell transplantation than in the historical control group (hazard ratio: 2.81 and 95% confidence interval 1.16-6.85); moreover, no safety concerns were observed. CONCLUSIONS: Our findings strongly suggest that autologous CD34 + cell transplantation is a novel treatment option for fracture nonunion. TRIAL REGISTRATION: UMIN-CTR, UMIN000022814. Registered on 22 June 2016.2023年10月, BMC medicine, 21(1) (1), 386 - 386, 英語, 国際誌研究論文（学術雑誌）
- Abstract Coronavirus disease (COVID-19) often causes persistent symptoms long after infection, referred to as “long COVID” or post-acute COVID-19 syndrome (PACS). This phenomenon has been studied primarily concerning B-cell immunity, while the involvement of T-cell immunity is still unclear. This retrospective study aimed to examine the relationship among the number of symptoms, cytokine levels, and the Enzyme-linked immunosorbent spot (ELISPOT) assay data in patients with COVID-19. To examine inflammatory conditions, plasma interleukin (IL)-6, IL-10, IL-18, chemokine ligand 9 (CXCL9), chemokine ligand 3 (CCL3), and vascular endothelial growth factor (VEGF) levels were analyzed using plasma obtained from COVID-19 recovery patients and healthy controls (HC). These levels were significantly higher in the COVID-19 group than those in the HC group. ELISPOT assays were performed to investigate the correlation between COVID-19 persistent symptoms and T-cell immunity. Cluster analysis of ELISPOT categorized COVID-19 recovery patients in the ELISPOT-high and -low groups, based on the values of S1, S2, and N. The number of persistent symptoms was significantly higher in the ELISPOT-low group than those in the ELISPOT-high group. Thus, T cell immunity is critical for the rapid elimination of COVID-19 persistent symptoms, and its measurement immediately after COVID-19 recovery might predict long-term COVID-19 or PACS.Springer Science and Business Media LLC, 2023年07月, Scientific Reports, 13(1) (1), 11071 - 11071, 英語, 国際誌研究論文（学術雑誌）
- Abstract Sinusoidal obstruction syndrome (SOS) is a fatal complication of hematopoietic stem cell transplantation (HSCT). Early diagnosis for SOS can improve clinical outcomes significantly. Here, we performed a retrospective study to investigate the Cairo diagnostic criteria, in which SOS was defined as the development of two or more in seven events, including transfusion‐refractory thrombocytopenia. Among 154 cases of allogeneic HSCT, 10 cases of SOS using the European Society for Blood and Marrow Transplantation criteria (EBMT16) as the reference standard were identified. The original Cairo criteria could diagnose SOS 5 days earlier than any other established criteria, with some false‐positive results (sensitivity = 100.0%; specificity = 72.2%). When the cutoff was set to three events for the Cairo criteria, the diagnosis of SOS could be made 3 days earlier than that using the EBMT16 criteria, with comparable precision (specificity = 86.1%). The accuracy of the Cairo criteria improved further when the cutoff point was set to four (specificity = 93.8%). The fulfillment of the Cairo criteria was associated with high mortality. Based on our results, the Cairo criteria were also considered clinically useful, especially at three or four cutoff points. Further studies are required to validate and refine the criteria.Wiley, 2023年06月, eJHaem, 4(3) (3), 695 - 704, 英語, 国際誌研究論文（学術雑誌）
- Hyperglycemia in the early days following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a well-known risk factor for acute graft-versus-host disease (GVHD) and non-relapse mortality. The FreeStyle Libre Pro, a factory calibrated continuous glucose monitoring (CGM) device, has been used for the retrospective analysis of glucose testing in patients with diabetes. We assessed the safety and accuracy of the device in patients undergoing allo-HSCT. We recruited eight patients who underwent allo-HSCT between August 2017 and March 2020. They wore the FreeStyle Libre Pro on the day before or on the day of transplantation until 28 days after transplantation. Adverse events, especially bleeding and infection, were monitored to assess safety, and blood glucose levels were measured and compared with the device values. None of the eight participants experienced bleeding that was difficult to stop from the sensor site or local infection that required antimicrobial administration. The device value was well correlated with blood glucose (correlation coefficient r=0.795, P<0.01); however, the overall mean absolute relative difference was 32.1%±16.0%. Our study demonstrated the safety of FreeStyle Libre Pro in allo-HSCT patients. However, the sensor results tended to be lower than the blood glucose levels.2023年05月, Blood cell therapy, 6(2) (2), 54 - 60, 英語, 国内誌研究論文（学術雑誌）
- Global longitudinal strain (GLS), a new cardiac parameter measured by the speckle-tracking method, is reportedly more sensitive than ejection fraction (EF) in detecting slight cardiac dysfunction in heart failure patients. We validated the utility of GLS in allogeneic hematopoietic stem cell transplantation (HSCT) patients during a long-term follow-up. Medical records of patients who underwent allogeneic HSCT between 2013 and 2020 were reviewed retrospectively. We evaluated the last echocardiography performed before transplantation and those performed annually during the 5 years after transplantation. We also investigated newly diagnosed cardiac events, which developed after HSCT. Among 85 patients, 22 used cardioprotective drugs. The median follow-up duration in surviving patients was 54.1 months (range, 2.9-92.6 months). GLS significantly decreased year by year, and patients taking cardioprotective agents tended to have a better GLS at 5 years than at 3 years, while EF did not change. Fifteen patients developed newly diagnosed cardiac events. Multivariate analysis revealed that low GLS and high serum ferritin levels at baseline were independently associated with the development of cardiac events. Therefore, we need a continuous follow-up of cardiac function by GLS and prescription of cardioprotective drugs might be considered for HSCT patients with low GLS. Further research is warranted.2023年02月, EJHaem, 4(1) (1), 192 - 198, 英語, 国際誌研究論文（学術雑誌）
- In acute myeloid leukemia (AML), the heterogeneity of genetic and epigenetic characteristics makes treatment difficult. The prognosis for AML is therefore poor, and there is an urgent need for new treatments for this condition. Gemtuzumab ozogamicin (GO), the first antibody-drug conjugate (ADC), targets the CD33 antigen expressed in over 90% of AML cases. GO therefore has the potential to counter the heterogeneity of AML patients. However, a major clinical problem is that drug resistance to GO diminishes its effect over time. Here, we report that the inhibition of glycogen synthase kinase 3 (GSK3) alone overcomes several forms of GO resistance at concentrations without antileukemic effects. The GSK3 inhibitors tested significantly enhanced the cytotoxic effect of GO in AML cell lines. We elucidated four mechanisms of enhancement: (1) increased expression of CD33, the target antigen of GO; (2) activation of a lysosomal function essential for hydrolysis of the GO linker; (3) reduced expression of MDR1 that eliminates calicheamicin, the payload of GO; and (4) reduced expression of the anti-apoptotic factor Bcl-2. A similar combination effect was observed against patient-derived primary AML cells. Combining GO with GSK3 inhibitors may be efficacious in treating heterogeneous AML.2023年02月, EJHaem, 4(1) (1), 153 - 164, 英語, 国際誌研究論文（学術雑誌）
- We previously reported that a second dose of BNT162b2 was safe and effective for allogeneic hematopoietic stem cell transplantation (HSCT) patients. Here, we investigated the safety and efficacy of a third dose of COVID-19 mRNA vaccine in allogeneic HSCT patients. Antibody titers against the S1 spike protein were measured using the QuaResearch COVID-19 Human IgM IgG ELISA kit. The previous study included 25 allogeneic HSCT patients who received two doses of BNT162b2. Following the exclusion of three patients because of the development of COVID-19 (n = 2) and loss to follow-up (n = 1), the study evaluated 22 allogeneic HSCT patients who received a third dose of COVID-19 mRNA vaccine (BNT162b2 [n = 15] and mRNA-1273 [n = 7]). Median age at the time of the first vaccination was 56 (range, 23-71) years. Five patients were receiving immunosuppressants at the third vaccination, namely calcineurin inhibitors (CI) alone (n = 1), steroids alone (n = 2), or CI combined with steroids (n = 2). Twenty-one patients (95%) seroconverted after the third dose. None of our patients had serious adverse events, new-onset graft-versus-host disease (GVHD), or GVHD exacerbation after vaccination. A third dose of the BNT162b2 and mRNA-1273 COVID-19 vaccines was safe and effective for allogeneic HSCT patients.2022年10月, Vaccines, 10(11) (11), 英語, 国際誌研究論文（学術雑誌）
- To elucidate the long-term outcomes of non-anthracycline-containing therapies and central nervous system (CNS) events in patients with extranodal NK/T-cell lymphoma, nasal type (ENKTL), the clinical data of 313 patients with ENKTL diagnosed between 2000 and 2013 in a nationwide retrospective study in Japan were updated and analyzed. At a median follow-up of 8.4 years, the 5-year overall survival (OS) and progression-free survival (PFS) were 71% and 64%, respectively, in 140 localized ENKTL patients who received radiotherapy-dexamethasone, etoposide, ifosfamide, and carboplatin (RT-DeVIC) in clinical practice. Nine (6.4%) patients experienced second malignancies. In 155 localized ENKTL patients treated with RT-DeVIC, 10 (6.5%) experienced CNS relapse (median, 12.8 months after diagnosis). In five of them, the events were confined to the CNS. Nine of the 10 patients who experienced CNS relapse died within 1 year after CNS relapse. Multivariate analysis identified gingival (hazard ratio [HR], 54.35; 95% confidence interval [CI], 8.60-343.35) and paranasal involvement (HR, 7.42; 95% CI, 1.78-30.89) as independent risk factors for CNS relapse. In 80 advanced ENKTL patients, 18 received steroid (dexamethasone), methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy as first-line treatment. Patients who received SMILE as their first-line treatment tended to have better OS than those who did not (p = 0.071). Six (7.5%) advanced ENKTL patients experienced isolated CNS relapse (median, 2.6 months after diagnosis) and died within 4 months of relapse. No second malignancies were documented in advanced ENKTL patients. In the entire cohort, the median OS after first relapse or progression was 4.6 months. 12 patients who survived 5 years after PFS events were disease-free at the last follow-up. Of those, 11 (92%) underwent hematopoietic stem cell transplantation. Our 8-year follow-up revealed the long-term efficacy and safety of RT-DeVIC and SMILE. The risk of CNS relapse is an important consideration in advanced ENKTL.2022年10月, Hematological oncology, 40(4) (4), 667 - 677, 英語, 国際誌研究論文（学術雑誌）
- Asciminib, a first-in-class, allosteric inhibitor of BCR-ABL1 that acts by STAMP (Specifically Targeting the ABL Myristoyl Pocket), is a novel therapeutic option for patients with chronic myeloid leukemia (CML). In the global, phase 3, open-label ASCEMBL study in patients with CML in chronic phase (CML-CP) pretreated with ≥2 tyrosine kinase inhibitors (TKIs) (NCT03106779), asciminib (40 mg twice-daily) demonstrated significant superiority over the ATP-competitive TKI bosutinib (500 mg once daily) for the primary endpoint of major molecular response (MMR; BCR::ABL1 transcript levels on the international scale [BCR::ABL1IS ] ≤0.1%) at week 24. Here, we report results from a descriptive subgroup analysis of Japanese patients enrolled in ASCEMBL study (data cut-off: May 25, 2020). Overall, 16 Japanese patients were randomized (asciminib, n = 13; bosutinib, n = 3). At week 24, the MMR rate with asciminib was 30.8% (4/13; 95% confidence interval [CI], 9.09-61.43). BCR::ABL1IS ≤1% and complete cytogenic response (CCyR) at week 24 were 61.5% (8/13 patients) and 50.0% (4/8 patients), respectively. In the bosutinib group, no patient achieved MMR, CCyR, or BCR::ABL1IS ≤1%, but results were limited by the low number of patients. The safety profile of asciminib was comparable to that previously observed in the overall study population. Findings from this Japanese subgroup analysis of the ASCEMBL study support the use of asciminib for the treatment of Japanese patients with CML-CP previously treated with ≥2 TKIs. ClinicalTrials.gov Identifier: NCT03106779.2022年09月, Cancer medicine, 12(3) (3), 2990 - 2998, 英語, 国際誌研究論文（学術雑誌）
- An acute promyelocytic leukemia (APL) patient not demonstrating the retinoic acid receptor α (RARA) translocation is rare. A 76-year-old man was diagnosed with myelodysplastic syndrome (MDS). After a year, abnormal promyelocytes were detected with pancytopenia and disseminated intravascular coagulopathy. Morphologically, the patient was diagnosed with APL; however, a genetic examination failed to detect RARA translocation. Thereafter, whole-genome sequencing revealed an NRAS missense mutation [c.38 G>A (p.G13D)]. This mutation was not detected in posttreatment bone marrow aspirate, despite residual MDS. Few reports are available on similar cases. Furthermore, the NRAS c.38 G>A mutation may be a novel pathogenic variant exacerbating RARA translocation-negative acute promyelocytic-like leukemia.2022年09月, Internal medicine (Tokyo, Japan), 62(9) (9), 1329 - 1334, 英語, 国内誌研究論文（学術雑誌）
- (一社)日本医療検査科学会, 2022年08月, 医療検査と自動化, 47(4) (4), 455 - 455, 日本語
- Anti-CD20 antibodies react with CD20 expressed not only on malignant B cells, but also on normal B cells. It has been reported that patients treated with anti-CD20 antibodies had an insufficient response to two-dose mRNA SARS-CoV-2 vaccination. To investigate the efficacy of a third dose in these patients, we investigated serum IgG antibody titers for the S1 protein after a third vaccination in 22 patients treated with the anti-CD20 antibody who failed two-dose vaccination. Results showed that overall, 50% of patients seroconverted. Although no patient who received the third dose within 1 year of the last anti-CD20 antibody administration showed an increase in S1 antibody titer, 69% of patients who received the third dose more than 1 year after the last anti-CD20 antibody administration seroconverted. Our data show that a third dose of vaccination is effective in improving the seroconversion rate in patients treated with the anti-CD20 antibody who failed standard two-dose vaccination.2022年06月, Vaccines, 10(6) (6), 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Recent pivotal phase III trials involving direct oral anticoagulant (DOAC) versus low molecular weight heparin have demonstrated the utility of DOACs in Western patients with cancer-associated venous thromboembolism (VTE). However, these trials did not include Japanese patients. This phase II trial evaluated the safety and efficacy of apixaban in Japanese patients with cancer-associated VTE (UMIN000028447). METHOD AND RESULTS: Apixaban was initiated at 10 mg twice daily for 7 days, followed by 5 mg twice daily for 23 weeks. The primary endpoint was the incidence of major or clinically relevant non-major (CRNM) bleeding events during the treatment period. The study was terminated due to safety concerns after enrolling 27 patients. Median age was 71 years; median body weight was 51.3 kg; and major primary tumor sites were the gastrointestinal tract (26%) and lung (19%). During the median follow-up period of 5.4 months, major or CRNM bleeding occurred in in 26% of patients (major, n = 5; CRNM, n = 2; 95% confidence interval, 11-46%). No recurrent VTE or VTE-related death occurred. Estimated overall survival at 6 months was 68%. CONCLUSION: This study demonstrated the excessive bleeding risk of apixaban at the standard dose in Japanese patients with cancer-associated VTE.2022年04月, International journal of hematology, 115(4) (4), 499 - 507, 英語, 国内誌研究論文（学術雑誌）
- Patients who have undergone hematopoietic stem cell transplantation (HSCT) for hematological disease experience high mortality when infected by coronavirus disease 2019 (COVID-19). However, the safety and efficacy of the COVID-19 vaccine in HSCT patients remain to be investigated. We prospectively evaluated the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine (Pfizer BioNTech) in 25 Japanese allogeneic HSCT patients in comparison with 19 healthy volunteers. While anti-S1 antibody titers in almost all healthy volunteers after the second dose were higher than the cut-off value reported previously, levels in HSCT patients after the second dose were diverse. Nineteen patients (76%) had seroconversion of anti-S1 IgG. The median optical density of antibody levels in HSCT patients with low IgG levels (<600 mg/dL), steroid treatment, or low lymphocytes (<1000/μL) was significantly lower than that in the other HSCT patients. There were no serious adverse events (>Grade 3) and no new development or exacerbation of graft-versus-host disease after vaccination. We concluded that the BNT162b2 mRNA vaccine is safe and effective in Japanese allogeneic HSCT patients.2022年01月, Vaccines, 10(2) (2), 英語, 国際誌研究論文（学術雑誌）
- (株)メディカルレビュー社, 2022年01月, がん分子標的治療, 19(2) (2), 192 - 195, 日本語
- We investigated the efficacy of BNT162b2 mRNA COVID-19 vaccine in patients with B-cell malignancies treated with anti-CD20 antibody. Although T-cell-mediated immune responses were detected even in patients receiving R-CHOP treatment, the S1 antibody titer following BNT162b2 vaccination remained only marginally increased for more than 3 years after the final dose of anti-CD20 antibody. We found no relationship between the percent of B-cells and S1 antibody titer. The duration of this suppression was much longer than we anticipated. Further protection and treatment strategies against COVID-19 for these patients are warranted.2022年01月, International journal of hematology, 115(1) (1), 7 - 10, 英語, 国内誌研究論文（学術雑誌）
- (株)メディカルレビュー社, 2021年09月, がん分子標的治療, 19(1) (1), 131 - 132, 日本語
- The t(1;11)(p32;q23) translocation is a rare but recurrent cytogenetic aberration in acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (B-ALL). This translocation was initially shown to form a fusion gene between KMT2A exon 8 at 11q23 and EPS15 exon 2 at 1p32 in AML. Activating mutations of FLT3 are frequently found in AML but are very rare in ALL. Here, we describe a 75-year-old woman who was diagnosed with B-ALL since her bone marrow was made up of 98.2% lymphoblasts. These blasts were positive for CD19, CD22, CD79a, CD13, and CD33 but negative for CD10 and myeloperoxidase. The karyotype by G-banding and spectral karyotyping was 46,XX,t(1;11)(p32;q23). Expression of KMT2A/EPS15 and reciprocal EPS15/KMT2A fusion transcripts were shown: KMT2A exon 8 was in-frame fused to EPS15 exon 12, indicating that this fusion transcript was a novel type. Considering three reported B-ALL cases, EPS15 breakpoints were markedly different between AML (exon 2) and B-ALL (exons 10-12). Furthermore, an uncommon type of FLT3 mutation in the juxtamembrane domain was detected: in-frame 4-bp deletion and 10-bp insertion. Accordingly, our results indicate that the novel type of KMT2A/EPS15 fusion transcript and FLT3 mutation may cooperate in the pathogenesis of adult B-ALL as class II and class I mutations, respectively.2021年06月, Cancer genetics, 254-255, 92 - 97, 英語, 国際誌研究論文（学術雑誌）
- Springer Science and Business Media LLC, 2021年03月, SN Comprehensive Clinical Medicine, 3(6) (6), 1455 - 1462研究論文（学術雑誌）
- Regorafenib is an oral multi-kinase inhibitor which targets tumor angiogenesis, the tumor microenvironment and oncogenesis. Based on this mode of action, regorafenib has a broad spectrum of toxicities. However, at present, few reports have focused on autoimmune adverse events. We report a first case of regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission during treatment for the patients with heavily treated advanced colorectal cancer. This case report highlights the need for caution with regard to regorafenib treatment in patients with cancer with concomitant immune thrombocytopenic purpura.2021年02月, Molecular and clinical oncology, 14(2) (2), 30 - 30, 英語, 国際誌研究論文（学術雑誌）
- Birt-Hogg-Dubé (BHD) syndrome is an autosomal dominant disease characterized by benign skin hamartomas, pulmonary cysts leading to spontaneous pneumothorax, and an increased risk of renal cancer. BHD syndrome is caused by germline mutations in the folliculin (FLCN) gene, a putative tumor suppressor, which result in loss of function of the folliculin protein and may cause cancer predisposition. In a 45-year-old woman with anemia, lymphadenopathy, and a history of recurrent spontaneous pneumothorax, 18F-FDG PET/CT detected diffuse and slight 18F-FDG accumulation in the bone marrow, enlarged spleen, and systemic multiple enlarged lymph nodes. Genetic examination identified a germline nonsense mutation [c.998C > G (p.Ser333*)] on exon 9 of FLCN. Pathological examination of the lymph node revealed a diffuse neoplastic proliferation of plasmacytoid lymphocytes. The neoplastic lymphoid cells were positive for CD20, CD138, and light chain kappa as per immunohistochemistry and mRNA in situ hybridization, and a MYD88 gene mutation [c.755T > C (p.L252P)] was identified. Accordingly, she was diagnosed with lymphoplasmacytic lymphoma concomitant with BHD syndrome. To the best of our knowledge, this is the first report describing the development of hematological malignancy in a patient with BHD syndrome. The FLCN mutation might contribute lymphomagenesis as an additional mutation cooperating with the MYD88 mutation.Springer Science and Business Media LLC, 2020年12月, International Journal of Hematology, 112(6) (6), 864 - 870, 英語, 国内誌研究論文（学術雑誌）
- Disseminated cryptococcosis, usually involving the lungs and central nervous system, carries a high risk of morbidity and mortality in immunocompromised hosts. In this report, we describe a case of miliary pulmonary cryptococcosis in a patient with acute myeloid leukemia, initially resembling miliary tuberculosis. The diagnosis of disseminated cryptococcosis was made based on transbronchial lung biopsy with subsequent detection of Cryptococcus neoformans in blood and cerebrospinal fluid. The patient was treated with liposomal amphotericin B as induction therapy, followed by fluconazole as consolidation and maintenance therapies thereafter. The infection was improved immediately, and he successfully underwent hematopoietic stem cell transplantation. The present case serves as a timely reminder that a radiological miliary pattern necessitates a thorough search for a definitive microbiological and histopathological diagnosis.Elsevier BV, 2020年11月, Journal of Infection and Chemotherapy, 26(11) (11), 1216 - 1219, 英語, 国際誌研究論文（学術雑誌）
- (一社)日本循環器学会, 2020年07月, 日本循環器学会学術集会抄録集, 84回, PE52 - 6, 英語Bleeding Events Associated with Anticoagulant Therapy; Apixaban in Japanese Patients with Cancer-associated Venous Thromboembolism: A Multicenter Phase II Trial(J-CAV)(和訳中)
- In this phase II multicenter study (JALSG AML209-FLT3-SCT), we aimed to prospectively elucidate the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) at first complete remission (CR1) for FLT3-internal tandem duplication (ITD)-positive AML. Newly diagnosed de novo AML patients with FLT3-ITD were enrolled at the achievement of CR1 and received allo-HSCT as soon as possible after the first consolidation therapy. Mutations of 57 genes in AML cells at diagnosis were also analyzed. Among 48 eligible patients with a median age of 38.5 (17-49) years, 36 (75%) received allo-HSCT at a median of 108 days after CR1. The median follow-up was 1726 days. The primary end-point, 3-year disease-free survival (DFS) based on an intent to treat analysis, was 43.8% (95% confidence interval [CI], 30%-57%), suggesting the efficacy of this treatment because the lower limit of the 95% CI exceeded the threshold response rate of 20%. The 3-year overall survival, post-transplant DFS, and non-relapse mortality rates were 54.2% (95% CI, 39%-67%), 58.3% (95% CI, 41%-72%), and 25.0% (95% CI, 12%-40%), respectively. The median ITD allelic ratio (AR) was 0.344 (0.006-4.099). Neither FLT3-ITD AR nor cooccurring genetic alterations was associated with a poor DFS. This prospective study indicated the efficacy and safety of allo-HSCT for FLT3-ITD AML patients in CR1. This study was registered at: www.umin.ac.jp/ctr/ as #UMIN000003433.2020年07月, Cancer science, 111(7) (7), 2472 - 2481, 英語, 国際誌研究論文（学術雑誌）
- Autoimmune hemolytic anemia (AIHA) is a rare comorbidity in colorectal cancer (CRC) and has an unknown etiology. Previously, we described an AIHA case secondary to CRC with ectopic band 3 expression. Herein, we investigated ectopic band 3 expression and erythrocyte membrane-bound IgG in a CRC cohort. Between September 2016 and August 2018, 50 patients with CRC and 26 healthy controls were enrolled in the present study. The expression of band 3 and SLC4A1 mRNA was observed in 97% of CRC surgical specimens. Although clinical AIHA was not observed in any patient with CRC, a direct antiglobulin test was positive in 10 of the patients in the CRC group (p = 0.01). Flow cytometry revealed significantly increased erythrocyte membrane-bound IgG among patients with CRC compared to healthy controls (mean ± standard deviation; 38.8 ± 4.7 vs. 29.9 ± 15.6, p = 0.012). Normocytic anemia was observed, including in cases negative for fecal occult blood, suggesting a shortened erythrocyte life-span due to increased membrane-bound IgG. Immunoprecipitation revealed increased anti-band 3 autoantibodies in patients' sera. Mouse experiments recapitulated this phenomenon. We also confirmed that band 3 expression is controlled by 5'AMP-activated protein kinase under hypoxic conditions. These findings increase our understanding of the etiology of cancer-related anemia.2020年05月, International journal of hematology, 111(5) (5), 657 - 666, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- In multiple myeloma (MM), MYC rearrangements that result in increased MYC expression are associated with an aggressive form of MM and adverse outcome. However, the consequences of MYC amplification in MM remain unclear. Here, we describe an unusual case of plasma cell leukemia (PCL) harboring MYC amplification on double minute chromosomes (dmin). A 79-year-old woman was initially diagnosed as having BJP-κ type MM with bone lesions. After seven months, the disease progressed to secondary PCL: leukocytes 49.1 × 109/L with 77% plasma cells showing lymphoplasmacytic appearance. The bone marrow was infiltrated with 76% plasma cells immunophenotypically positive for CD38 and negative for CD45, CD19, CD20, and CD56. The karyotype by G-banding and spectral karyotyping was 48,XX,der(14)t(11;14)(q13;q32),+der(14)t(14;19)(q32;q13.1),+18,6~95dmin[15]/46,XX[5]. Fluorescence in situ hybridization detected multiple MYC signals on dmin and double IGH/CCND1 fusion signals on der(14)t(11;14) and der(14)t(14;19). Most plasma cells were diffusely and strongly positive for MYC and CCND1 by immunohistochemistry. The patient died of progressive disease after one week. MYC amplification led to high expression of MYC and rapid disease progression, indicating its clinical significance in the pathogenesis of MM/PCL. MYC amplification on dmin may be a very rare genetic event closely associated with the progression to PCL and coexistence of IGH/CCND1 fusions.Elsevier BV, 2020年04月, Cancer Genetics, 242, 35 - 40, 英語, 国際誌研究論文（学術雑誌）
- Acute myeloid leukemia (AML) with an inv(16)(p13q22) or t(16;16)(p13;q22) chromosomal abnormality represents one of the most common subtypes of de novo cases. These chromosomal rearrangements result in multiple CBFB-MYH11 fusion transcripts, with type-A being the most frequent. We here describe a unique case of de novo AML-M1, with inv(16)(p13q22), leading to an unusual CBFB-MYH11 fusion transcript, and der(7)t(7;11)(q31;q21). The fusion transcript involves a CBFB exon 5 with a breakpoint at nucleotide 754, an insertion of a 13-bp sequence of CBFB intron 5 at the fusion point, and the MYH11 exon 27 with a breakpoint at nucleotide 3464. To our knowledge, this CBFB-MYH11 fusion transcript has never been reported previously. The clinical characteristics of the present case are in line with previous reports suggesting that rare CBFB-MYH11 fusion transcripts lead to aberrant characteristics such as an atypical cytomorphology and additional cytogenetic abnormalities.2020年02月, Cancer genetics, 241, 72 - 76, 英語, 国際誌研究論文（学術雑誌）
- OBJECTIVE: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event experienced by cancer patients. In general, CIPN is evaluated subjectively based on patient self-assessment or clinician-reported scales; evidence supporting the utility and validity of quantitative sensory tests (QST) is lacking in this patient population. The aim of this study was to objectively assess CIPN of lower extremities by QSTs, and to evaluate the concordance between QSTs and subjective assessments. METHODS: In this prospective cohort study, outpatients with cancer receiving chemotherapy were recruited at a single university hospital. We assessed CIPN at the lower extremities at baseline and three months after baseline. The QSTs were performed by applying a monofilament and a tuning fork to determine touch and vibration thresholds, respectively, at the affected site. Subjective assessments were performed based on the visual analog scale (VAS) and the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) toxicity grade. Kappa coefficients were calculated to evaluate the concordance between QSTs and subjective assessments. RESULTS: After exclusion and drop-outs during follow-up, nineteen patients were included in the analysis. The prevalence of patients with abnormal sensation was 37% based on QSTs, 32% based on the VAS, and 14% based on CTCAE grading, respectively. Kappa coefficients were 0.32 between QSTs and VAS, and 0.28 between QSTs and CTCAE. CONCLUSIONS: The concordance rates between quantitative and subjective assessments were low. CIPN should be assessed using both quantitative and subjective assessments.2020年, Physical therapy research, 23(2) (2), 166 - 171, 英語, 国内誌研究論文（学術雑誌）
- Springer Science and Business Media LLC, 2019年11月, International Journal of Hematology, 110(5) (5), 521 - 523, 英語, 国内誌研究論文（学術雑誌）
- Gemtuzumab ozogamicin (GO), an anti-CD33 antibody linked to calicheamicin via an acid-labile linker, is the first antibody-drug conjugate (ADC). The acidic environment inside lysosomes of target cells is an important intracellular determinant of the cytocidal action of GO, as the linker is hydrolyzed under acidic conditions. However, lysosomal activity in acute myeloid leukemia (AML) blasts in GO therapy has been insufficiently evaluated. It has been suggested that lysosome activity is suppressed in AML due to hyperactivation of the phosphoinositide 3-kinase/Akt pathway. We therefore hypothesized that agents which activate lysosomal function would potentiate the cytotoxicity of GO. Here, we found that a clinically useful mTORC1/2 dual inhibitor, AZD2014, reduced pH in the acidic organelles, including lysosomes, as shown by increased LysoTracker fluorescent intensity, and synergistically enhanced the cytotoxic effect of GO in primary leukemia cells. GO-induced cytotoxicity appeared to be enhanced with the increase in lysosomal activity by AZD2014. These results indicate that AZD2014 activated lysosomal function in primary leukemia cells, which in turn enhanced the cytotoxicity of GO. Enhancement of lysosomal activity may represent a new therapeutic strategy in the treatment of GO and other ADCs, particularly in cases with low lysosomal activity.2019年10月, International journal of hematology, 110(4) (4), 490 - 499, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- Protein kinase N1 (PKN1) knockout (KO) mice spontaneously form germinal centers (GCs) and develop an autoimmune-like disease with age. Here, we investigated the function of PKN1 kinase activity in vivo using aged mice deficient in kinase activity resulting from the introduction of a point mutation (T778A) in the activation loop of the enzyme. PKN1[T778A] mice reached adulthood without external abnormalities; however, the average spleen size and weight of aged PKN1[T778A] mice increased significantly compared to aged wild type (WT) mice. Histologic examination and Southern blot analyses of spleens showed extramedullary hematopoiesis and/or lymphomagenesis in some cases, although without significantly different incidences between PKN1[T778A] and WT mice. Additionally, flow cytometry revealed increased numbers in B220+, CD3+, Gr1+ and CD193+ leukocytes in the spleen of aged PKN1[T778A] mice, whereas the number of lymphocytes, neutrophils, eosinophils, and monocytes was reduced in the peripheral blood, suggesting an advanced impairment of leukocyte trafficking with age. Moreover, aged PKN1[T778A] mice showed no obvious GC formation nor autoimmune-like phenotypes, such as glomerulonephritis or increased anti-dsDNA antibody titer, in peripheral blood. Our results showing phenotypic differences between aged Pkn1-KO and PKN1[T778A] mice may provide insight into the importance of PKN1-specific kinase-independent functions in vivo.2019年09月, Scientific reports, 9(1) (1), 13977 - 13977, 英語, 国際誌研究論文（学術雑誌）
- Alemtuzumab is the treatment choice for patients with T-prolymphocytic leukemia (T-PLL). However, patients with T-PLL have a poor prognosis, and the option of allogeneic hematopoietic cell transplantation (HCT) remains controversial in these patients. This study aimed to analyze the outcomes of allogeneic HCT among patients with T-PLL to identify the potential clinical efficacy of allogeneic HCT. We retrospectively analyzed data from 20 patients with T-PLL, including five patients with complex chromosomal abnormalities at diagnosis who received an allogeneic HCT between 2000 and 2016. The median follow-up of survivors was 51 months in allogeneic HCT from human leukemia antigen (HLA)-matched donors. All five patients with complex chromosomal abnormalities died after allogeneic HCT. Our data suggest that allogeneic HCT from an HLA-matched donor can be considered for patients with T-PLL without complex chromosomal abnormalities. New treatment strategies of allogeneic HCT are required to improve the safety and efficacy of allografting in patients with T-PLL and complex chromosomal abnormalities. Potential approaches that identify patients with T-PLL and complex chromosomal abnormalities for allogeneic HCT with better disease control may allow identification of individuals who are suitable for allogeneic HCT.2019年09月, Annals of hematology, 98(9) (9), 2213 - 2220, 英語, 国際誌研究論文（学術雑誌）
- Extranodal NK/T cell lymphoma (NKTCL), nasal type (ENKL) that shows no apparent nasal involvement, is termed extranasal NKTCL or non-nasal NKTCL. In this study, we aimed to explore therapeutic approaches and outcomes in patients with extranasal NKTCL in current clinical practice. A data set of patients with newly diagnosed NKTCL who were diagnosed at 31 institutes in Japan between 2000 and 2013 was used for analysis. The patients' fitness for steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy was assessed using the major inclusion criteria of the SMILE phase 2 study. Of 358 patients, 47 (13%) had extranasal NKTCL. The most frequent extranodal sites of involvement in extranasal NKTCL were skin/subcutaneous tissue (n = 18). Six (13%) of the patients with extranasal NKTCL had localized disease and were diagnosed before 2010. With a median follow-up of 5.8 years, the 2-year overall survival (OS) in patients with nasal and extranasal NKTCL was 70% (95% confidence interval [CI], 65-75%) and 34% (95% CI, 21-47%), respectively. OS in patients with nasal NKTCL had a trend toward better according to treatment era (P = 0.063). In contrast, no obvious improvement of OS was observed in extranasal NKTCL (P = 0.43). The major inclusion criteria of the SMILE-P2 were met in 21% (10/47) of patients with extranasal NKTCL and 60% (188/311) of those with nasal NKTCL (P < 0.001). Despite the advent of new treatments for ENKL, OS remains unfavorable in extranasal NKTCL. A more effective therapy is needed for extranasal NKTCL.2019年07月, Annals of hematology, 98(7) (7), 1647 - 1655, 英語, 国際誌研究論文（学術雑誌）
- Double-hit lymphoma is typically categorized as "high-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements", but in infrequent cases in which terminal deoxynucleotidyl transferase (TdT) expression is positive, it is categorized as B-lymphoblastic lymphoma (B-LBL). BCL2 rearrangements are usually caused by t(14;18)(q32;q21); variant translocations are very rare. Here, we describe an unusual case of double-hit pancreatic B-LBL with a variant translocation t(2;18)(p11;q21). A 69-year-old man was admitted because of an abdominal mass. Computed tomography scans demonstrated a diffusely enlarged pancreas and massive ascites. Cell block preparations of ascites cells revealed marked proliferation of blastic lymphoid cells positive for CD19, CD10, CD79a, PAX5, and TdT, indicating a diagnosis of B-LBL. G-banding and spectral karyotyping showed 45,XY,+X,t(2;18)(p11;q21),-4,der(5)t(1;5)(q12;p15),der(6)t(6;21)(q21;q?),t(8;14)(q24;q32),-15. Fluorescence in situ hybridization detected split BCL2 and IGH/MYC fusion signals. Almost all ascites cells were diffusely and strongly positive for MYC and BCL2. The patient died of progressive disease 20 days after admission. To our knowledge, this is the first reported case of MYC and BCL2 double-hit B-LBL with t(2;18)(p11;q21). High coexpression of MYC by t(8;14) and BCL2 by t(2;18) may be implicated in the development of B-LBL. Furthermore, double-hit B-LBL may be associated with a less favorable outcome compared with typical B-LBL.Springer Science and Business Media LLC, 2019年07月, International Journal of Hematology, 110(1) (1), 107 - 114, 英語, 国内誌研究論文（学術雑誌）
- 2019年05月, Leukemia & lymphoma, 60(5) (5), 1294 - 1298, 英語, 国際誌[査読有り]
- Chemotherapy-induced peripheral neuropathy (CIPN) frequently occurs in lymphoma patients receiving R-CHOP, a drug combination therapy. Although severe CIPN may lead to reduction and/or discontinuation of the medication, predictive factors of CIPN have not been investigated sufficiently to date. We performed a retrospective exploratory research to determine associations between prevalence of severe CIPN and sociodemographic data, health characteristics, and medical conditions such as anemia at initial diagnosis. Forty patients (indolent lymphoma, n = 9; diffuse large B-cell lymphoma; n = 31) received R-CHOP therapy from September 2009 to July 2014. The median age of patients was 58 years (range = 27-76 years). Statistical analyses were applied to the patients, who were divided into two groups: mild CIPN (no symptoms or grade 1 according to the CTCAE version 3.0 program) and severe CIPN patients (grade 2 or higher). Forward stepwise logistic regression analyses were performed using the following variables: sex, BMI, BSA, hyperglycemia, malnutrition, and anemia. Severe CIPN occurred in seven patients (17.5%). Gender and anemia remained following the stepwise procedure, and anemia predicted severe CIPN significantly (OR = 19.45, 95% confidence interval = 1.52-171.12). Our study suggests that anemia at initial diagnosis could be a predictive factor of R-CHOP-induced CIPN.2019年03月, Oncology research, 27(4) (4), 469 - 474, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- A 45-year-old woman was diagnosed with hepatosplenic T-cell lymphoma (HSTCL), a rare subtype of peripheral T-cell lymphoma. She received different types of chemotherapy, but disease progression was observed. To reduce the tumor burden before an unrelated bone marrow transplantation, combination chemotherapy consisting of the gemcitabine, carboplatin, and dexamethasone (GCD) was administered as bridging therapy, resulting in a reduction in the number of lymphoma cells. We were then able to perform bone marrow transplantation. Although she experienced some adverse events, she successfully achieved long-term remission. We herein report a successful case of HSTCL treated with unrelated stem cell transplantation following the GCD regimen as bridging chemotherapy.2019年03月, Intern Med., 58(5) (5), 707 - 712, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- BACKGROUND: Human herpesvirus 6 (HHV-6) encephalitis is a known life-threatening complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, few studies have focused on the occurrence of HHV-6 encephalitis in patients receiving mycophenolate mofetil (MMF) combined with a calcineurin inhibitor as prophylaxis for graft-versus-host disease (GVHD). This study aimed to investigate the impact of MMF administered for GVHD prophylaxis in the occurrence of HHV-6 encephalitis after allo-HSCT and the characteristics of this condition. METHODS AND RESULTS: We retrospectively analyzed 73 patients who underwent allo-HSCT (83 transplants) at our hospital between April 2010 and December 2015. MMF (2-3 g/d) was administered along with a calcineurin inhibitor. Seven patients (8.0%) developed encephalitis due to HHV-6. The median period from allo-HSCT to the onset of HHV-6 encephalitis was 23 days (range, 17-98 days). The cumulative incidence of HHV-6 encephalitis on day 100 after treatment was 12% and 6% in patients who underwent cord blood transplantation (CBT) and non-CBT (ie, bone marrow transplantation and peripheral blood stem cell transplantation), respectively (P = 0.344). Neurological symptoms of encephalitis were more severe in non-CBT cases than those in CBT cases. All patients diagnosed with HHV-6 encephalitis were treated with ganciclovir or foscarnet. None of the enrolled patients died from HHV-6 encephalitis. CONCLUSIONS: Mycophenolate mofetil may have the potential to increase the frequency of severe HHV-6 encephalitis in patients undergoing CBT and non-CBT. Thus, MMF should be administered with caution, and patients should be monitored closely for HHV-6 encephalitis even those who did not undergo CBT.2019年02月, Transpl Infect Dis., 21(1) (1), e13024, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- (一社)日本血液学会-東京事務局, 2019年01月, 臨床血液, 60(1号) (1号), 59 - 59, 日本語PET/MRI陰性だが頭部造影MRIにて中枢神経浸潤が明らかとなった精巣原発DLBCLの1例[査読有り]
- Scopulariopsis alboflavescens is a soil saprophyte that is widely distributed in nature. Recently, there have been increasing number of reports of invasive infections with Scopulariopsis species in immunocompromised patients. In this report, we described an adult woman with acute myeloid leukemia and who developed S. alboflavescens pneumonia. Liposomal amphotericin B and voriconazole combination therapy was unsuccessful and the patient died because of pneumonia. Scopulariopsis is highly resistant to available antifungal agents and almost invariably fatal. This case report should alert clinicians to the importance of listing Scopulariopsis as a pathogenic fungus in immunocompromised patients.2018年12月, Int J Hematol., 108(6) (6), 658 - 664, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- A 69-year-old woman who had been diagnosed with unresectable papillary thyroid cancer was referred to our hospital. We initially treated her with sorafenib, but she subsequently developed erythema multiforme, which was suspected to be a drug rush due to sorafenib; therefore, sorafenib was discontinued. At the time of discontinuation, immature blast cells were detected in her peripheral blood. Approximately two weeks later, her skin rash improved substantially, but the proportion of blasts in the peripheral blood increased. We performed a bone marrow examination, and she was diagnosed with FLT3-ITD-positive acute myeloid leukemia. FLT3-ITD expression is found in 20-25% of AML and is a known independent poor prognostic factor. To overcome the poor prognosis associated with FLT3-ITD, molecular drugs targeting FLT3-ITD are attracting much attention. Sorafenib, a multi-kinase inhibitor, also has an effect on FLT3-ITD. Although primary disease flares after tyrosine kinase inhibitor discontinuation have been reported, this is the first report to describe discontinuation of sorafenib treatment as a potential trigger of FLT3-ITD-positive acute myeloid leukemia in papillary thyroid cancer.2018年12月, J Oncol Pharm Pract, 25(8) (8), 2010 - 2015, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2018年12月, The Journal of dermatology, 45(12) (12), e337-e339 - e339, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- Gemtuzumab ozogamicin (GO), the first antibody-drug conjugate (ADC), has attracted the interest of hematologists because more than 90% of acute myeloid leukemia (AML) blasts express its target, CD33. Although GO and subsequently developed ADCs depend on lysosomes for activation, lysosome number and activity in tumor cells has not been well elucidated. In this study, we investigated whether an mTORC1/2 kinase inhibitor, PP242, which was reported to activate lysosomal function, potentiates the cytotoxicity of GO in AML cells. Eight AML cell lines (U937, THP-1, SKM-1, SKK-1, SKNO-1, HL-60, MARIMO and KO52) were treated with GO and PP242. The cytotoxic effect of GO was enhanced by concurrent treatment with a non-cytotoxic concentration (500 nM) of PP242 in most cell lines, except MARIMO and KO52 cells. We then used LysoTracker to label acidic lysosomes in U937, THP-1, SKM-1, MARIMO and KO52 cells. LysoTracker fluorescence was dramatically increased by treatment with PP242 in U937, THP-1 and SKM-1 cells, and the intensified fluorescence was retained with PP242 + GO. In contrast, PP242 did not induce a significant increase in fluorescence in MARIMO cells, consistent with the lack of combinatory cytotoxicity. LysoTracker fluorescence was also increased by PP242 in KO52 cells, which have been reported to strongly express multidrug resistance (MDR). Further, PP242 suppressed GO-induced Chk1 activation and G2/M cell cycle arrest, which in turn triggered cell cycle promotion and cell death. These results indicate that inhibition of mTORC1/2 kinase by PP242 enhanced the cytotoxicity of GO by increasing lysosomal compartments and promoting the cell cycle via suppression of GO-induced Chk1 activation. This combination may represent an attractive new therapeutic strategy for the treatment of leukemia.2018年11月, Leuk Res, 74, 68 - 74, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2018年11月, Leukemia & lymphoma, 59(11) (11), 2706 - 2710, 英語, 国際誌[査読有り]
- PURPOSE: The purpose of this study was to measure the frequency and identify factors associated with delayed socket healing after dental extraction in patients undergoing myelosuppressive chemotherapy for hematologic malignancy. MATERIALS AND METHODS: This prospective cohort study focused on delayed healing after extraction in patients with hematologic malignancy. Sockets with delayed healing were defined as those with intense pain and bone exposure 1 week postoperatively. Patients with and without delayed socket healing were compared using the Fisher exact test and Mann-Whitney U test with some variables. Receiver operating characteristics curve analysis was conducted to define cutoff values for delayed healing. RESULTS: One hundred ninety-four dental extractions in 93 patients (median age, 64 yr; range, 20 to 85 yr) were analyzed. The incidence of delayed socket healing was 7.5% (7 of 93 patients). There was no postoperative bleeding. Older age, type of hematologic malignancy (acute leukemia), shorter time from dental extraction to initiation of chemotherapy, low platelet count or hemoglobin level, requirement for red blood cell concentrate or platelet transfusion, and use of an absorbable hemostatic agent were statistically associated with the occurrence of delayed socket healing. Platelet and hemoglobin cutoffs were 4.6 × 104/μL and 7.7 g/dL, respectively. CONCLUSIONS: Although dental extraction can be safely performed in patients undergoing myelosuppressive chemotherapy for hematologic malignancy, oral surgeons should understand the potential risk for delayed socket healing. When considering dental extraction, patients with hematologic malignancy and low hemoglobin or platelet levels should be informed about the possibility of delayed socket healing.2018年10月, J Oral Maxillofac Surg, 76(10) (10), 2057 - 2065, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- (一社)日本血液学会-東京事務局, 2018年09月, 臨床血液, 59(9号) (9号), 1733 - 1733, 日本語多発性筋炎様症状を呈したNK/T細胞リンパ腫(Extranodal NK/T-cell lymphoma mimicking polymyositis)(英語)[査読有り]
- (一社)日本血液学会-東京事務局, 2018年09月, 臨床血液, 59(9) (9), 1640 - 1640, 英語新たなZMYND11/MBTD1融合遺伝子の発現とt(10;17)(p15;q21)転座を認めたCD7 CD56 急性骨髄性白血病(Expression of a novel ZMYND11/MBTD1 fusion transcript in CD7 CD56 AML with t(10;17)(p15;q21))(英語)[査読有り]研究論文（その他学術会議資料等）
- (一社)日本血液学会-東京事務局, 2018年09月, 臨床血液, 59(9号) (9号), 1815 - 1815, 日本語シクロスポリン療法後の骨髄移植にて重症肝類洞閉塞症候群をきたした一例(Severe sinusoidal obstruction syndrome after cyclosporine treatment followed by transplantation)(英語)[査読有り]
- (一社)日本血液学会-東京事務局, 2018年09月, 臨床血液, 59(9号) (9号), 1756 - 1756, 日本語TLR9の一塩基多型により無症候性CMV感染症を呈した再生不良性貧血の一例(Aplastic anemia that developed asymptomatic CMV infection due to SNPs of TLR9)(英語)[査読有り]
- (一社)日本腎臓学会, 2018年08月, 日本腎臓学会誌, 60(6号) (6号), 732 - 732, 日本語糖尿病性腎症に単クローン性ガンマグロブリン血症に関連したC3腎症を合併した1例研究論文（その他学術会議資料等）
- (一社)日本検査血液学会, 2018年06月, 日本検査血液学会雑誌, 19(学術集会) (学術集会), S182 - S182, 日本語[査読有り]
- BACKGROUND: CD134 (OX40), which is a cellular receptor for human herpesvirus-6B (HHV-6B) and expresses on activated T cells, may play a key role for HHV-6B replication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). OBJECTIVES: Therefore, we examined the CD134 expression on T cells and HHV-6B replication after allo-HSCT, and analyzed the correlation between them. STUDY DESIGN: Twenty-three patients after allo-HSCT were enrolled. The percentages of CD134-positive cells within the CD4+ and CD8+ cell populations were measured by flow cytometry, and the viral copy number of HHV-6B was simultaneously quantified by real-time PCR. The correlation between CD134 and HHV-6B viral load was then statistically analyzed. RESULTS: HHV-6B reactivation occurred in 11 of 23 patients (47.8%). CD134 expression was seen on T cells and was coincident with the time of peak viral load. The percentage of CD134-positive cells decreased significantly when HHV-6B DNA disappeared (p = .005 in CD4+ T cells, p = .02 in CD8+ T cells). In the 4 patients who underwent umbilical cord blood transplantation (UCBT), the viral load varied with the percentage of CD134-positive cells. In the comparison between the HHV-6B reactivation group and non-reactivation group, maximum percentages of CD134-positive cells among CD4+ T cells in reactivation group were significantly higher than those in non-reactivation group (p = .04). CONCLUSIONS: This is the first study to show that a correlation of CD134 expression on T cells with HHV-6B replication after allo-HSCT, especially in UCBT. The results possibly indicate that CD134 on T cells plays a key role for HHV-6B replication after allo-HSCT.2018年05月, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 102, 50 - 55, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- (一社)日本リウマチ学会, 2018年03月, 日本リウマチ学会総会・学術集会プログラム・抄録集 62回, 62回, 228 - 228, 日本語リウマチ性疾患の合併症・感染症とその対策 リウマチ患者に発生するリンパ増殖性疾患に対する血液内科的マネジメント 診断、経過観察、化学療法、予後などに関して[招待有り]
- PURPOSE: Mycophenolate mofetil (MMF) is increasingly used among Japanese patients undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT). Because pharmacokinetic data for MMF in the Asian population are limited, we conducted this investigation. METHODS: Intravenous MMF (1000 mg/dose) was administered to 10 patients along with cyclosporine or tacrolimus for 10 days after allo-SCT; it was administered every 8 h in peripheral blood stem cell- and bone marrow-transplanted patients, and every 12 h in cord blood-transplanted patients. MMF was administered orally at the same dose from day 11. Plasma concentrations of mycophenolic acid (MPA) were measured by high-performance liquid chromatography. RESULTS: The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively. The AUC0 - tau and Cmax were significantly higher after intravenous MMF dosing than after oral MMF dosing. All patients exhibited successful neutrophil engraftments in a median time of 18 days. Grade II acute graft-versus-host disease (GvHD) of the skin was observed in two patients, and one patient developed limited chronic GvHD. Individual cases of transient and curable grade III oral mucositis and diarrhea were observed; however, MMF was not discontinued. No other severe complications or infections were observed. CONCLUSIONS: Intravenously administered MMF was safe and possibly effective in achieving higher MPA plasma concentrations for GvHD prophylaxis after allo-SCT in Japanese patients.2018年03月, Cancer Chemother Pharmacol, 81(5) (5), 839 - 846, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- Immune reconstitution affects clinical outcomes after allogeneic hematopoietic stem cell transplantation (HSCT), and it has been suggested that lymphocyte recovery affects survival after HSCT. However, few studies have examined lymphocyte recovery in Asian patients who received mycophenolate mofetil (MMF) prophylaxis for graft-versus-host disease. We retrospectively evaluated early lymphocyte recovery after HSCT among Japanese adults who received MMF prophylaxis. Patients were divided into two groups according to their median absolute lymphocyte count (ALC) on day 28 after HSCT as follows: the "low ALC group" (≤ 0.22 × 109 cells/L) and the "high ALC group" (> 0.22 × 109 cells/L). With a median follow-up of 317 days, the high ALC group showed significantly better overall survival than the low ALC group (at 1 year: 62 vs. 46%, P = 0.02). The high ALC group also tended to have better non-relapse mortality than the low ALC group (at 1 year: 13 vs. 23%, P = 0.08). There was no significant difference in relapse rate between the high and low ALC groups (at 1 year: 29 vs. 35%, P = 0.2). We conclude that among Japanese patients who received MMF prophylaxis, ALC on day 28 after HSCT was effective in predicting overall survival and non-relapse mortality.2018年03月, Int J Hematol, 108(1) (1), 58 - 65, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- Lymph node infarction is very rare, and is frequently associated with neoplasms, such as malignant lymphoma and non-neoplastic disease, or interventions such as fine-needle aspiration (FNA). A 76-year-old-man presented with cervical lymph node swelling. Although FNA was performed, the findings were insufficient for a definitive diagnosis. Consequently, surgical biopsy of the cervical lymph node was performed, which revealed total infarction; a diagnosis of classical Hodgkin lymphoma was made later. Both lymphoma itself and FNA may cause total lymph node infarction, which makes diagnosis confusing. Therefore, it is important to repeat the biopsy rather than repeat FNA to correctly diagnose malignant lymphoma, including Hodgkin lymphoma.2018年03月, J Clin Exp Hematop., 58(1) (1), 24 - 26, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- S. Karger AG, 2018年02月, Cytogenetic and Genome Research, 153(3) (3), 131 - 137, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- Blackwell Publishing Ltd, 2018年01月, Journal of Dermatology, 45(1) (1), 64 - 66, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2017年12月, BLOOD, 130Improved Prognosis of Extranodal NK/T-Cell Lymphoma, Nasal Type (ENKL) of Nasal Origin but Not Extranasal Origin: An Analysis of NKEA Study[査読有り]
- 2017年12月, BLOOD, 130An mTORC1/2 Kinase Inhibitor Remarkably Enhances the Cytotoxicity of Gemtuzumab Ozogamicin By Activating Lysosomal Function and Cell Cycle Promotion in AML Cells[査読有り]
- 2017年12月, INTERNATIONAL JOURNAL OF HEMATOLOGY, 106(6) (6), 729 - 731, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- (一社)日本血液学会-東京事務局, 2017年11月, 臨床血液, 58(11号) (11号), 2289 - 2289, 日本語慢性C型肝炎治療後に発症したB細胞性前リンパ球性白血病の1例[査読有り]
- (一社)日本血液学会-東京事務局, 2017年09月, 臨床血液, 58(9号) (9号), 1763 - 1763, 日本語悪性リンパ腫患者におけるコリンエステラーゼ値層別化による腫瘍崩壊症候群発症リスクの後方視的解析[査読有り]
- 一般社団法人 日本血液学会, 2017年08月, 臨床血液, 58(8号) (8号), 938 - 941, 日本語, 国内誌
A 49-year-old female was initially diagnosed with acute myeloid leukemia (AML) M4 with a CD45＋CD13＋CD33＋CD34−HLA-DR＋ immunophenotype. She underwent allogeneic bone marrow transplantation, but the disease recurred. The bone marrow was infiltrated with 87.0% blasts negative for myeloperoxidase (MPO) staining. Immunophenotyping by flow cytometry identified the presence of a CD45-negative blast population. These blasts exhibited a CD13＋CD33＋CD19−CD10−CD34−HLA-DR− immunophenotype. The lack of CD45 expression is often observed in B-cell acute lymphoblastic leukemia, whereas CD45-negative AML is extremely rare; only one older male with AML-M0 has been reported. In the present case, the CD45-negative blasts had an MPO−CD13＋CD33＋ phenotype, which is similar to AML-M0.
[査読有り] - 2017年07月, PLOS ONE, 12(7) (7), e0182021, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- MDPI AG, 2017年03月, International Journal of Molecular Sciences, 18(3) (3), 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2017年02月, INTERNATIONAL JOURNAL OF HEMATOLOGY, 105(2) (2), 226 - 229, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- 日本皮膚科学会-大阪地方会・京滋地方会, 2016年12月, 皮膚の科学, 15(6号) (6号), 514 - 514, 日本語MALTリンパ腫が合併した抗セントロメア抗体と抗RNAポリメラーゼIII抗体が共に陽性を示した全身性強皮症の1例[査読有り]
- 2016年12月, INTERNATIONAL JOURNAL OF HEMATOLOGY, 104(6) (6), 682 - 691, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- 2016年11月, International journal of hematology, 104(5) (5), 531 - 533, 英語, 国内誌Sea-blue histiocytes in acute myeloid leukemia with trisomy 9.
- (公社)日本理学療法士協会, 2016年10月, 理学療法学, 43(Suppl.2) (Suppl.2), O - 6, 日本語客観的ツールで評価した化学療法誘発性末梢神経障害の経時的変化 その障害様式の調査[査読有り]研究論文（その他学術会議資料等）
- 【はじめに，目的】近年がん医療においては疾病の早期発見，治療法の発展により生存率が向上している一方で，治療による副作用が問題視されている。化学療法の副作用の1つに化学療法誘発性末梢神経障害（chemotherapy-induced peripheral neuropathy，以下，CIPN）があり，その好発部位から「手袋・靴下型」と称されている。リハビリテーション実施場面においても，化学療法実施中の患者にはしばしば見られる症状である。CIPNは多様な感覚器の障害様式を呈するが，その評価は医療者による主観的な評価が中心であり，どのような感覚器の障害様式なのかはについて詳細な評価はなされていない。本研究の目的は感覚検査の客観的評価ツール用い，CIPNを縦断的に調査し，その障害様式を明らかにすることである。【方法】本研究は前向きコホート研究であり，任意の化学療法実施日をベースラインとし，フォローアップ期間は3ヶ月とした。本研究の対象者は，2015年2月から7月までの期間内に，神戸大学医学部附属病院の通院治療室にて，副作用としてCIPNが出現する化学療法を受けているがん患者35名であり，脊椎疾患を有する者，フォロー不可能であった者，欠損値があった者を除く18名（63.7±11.3歳，女性11名）を解析対象者とした。CIPNの評価は下肢末端を評価部位とし，客観的評価として触覚検査，振動覚検査，主観的評価としてしびれについて検査を行った。触覚検査はモノフィラメント知覚テスターを用い，母趾指腹，母趾球，踵部，足首の四カ所の触覚を測定し，測定方法にはup and down methodを用いた。振動覚検査は音叉を用い，内果の振動覚を測定し，測定方法はtimed methodを用いた。しびれの主観的検査はVisual Analog Scale（以下，VAS）を用い前足部，足底部，足首の三カ所の主観的なしびれを評価した。測定はベースライン，フォローアップ時ともに化学療法実施日に行い，薬剤の投与前に上記評価を完了した。統計解析は対応のあるt検定およびWilcoxonの符号付順位検定を用い，それぞれの評価項目におけるベースライン時からフォローアップ時の値の変化を検討した。【結果】触覚検査では踵部のみに有意な変化がみられ，フォローアップ後に有意に触覚が低下していた（p＜0.01）。振動覚検査においてはフォロー後に有意に増悪がみられた（p＜0.01）。下肢末端のしびれの主観的検査においては前足部，足底部，足首部ともにフォロー後に有意差は見られなかった。【結論】三ヶ月のフォローアップ調査により，CIPNの障害様式は主に踵部の触覚低下および振動覚の低下であることが明らかとなった。一方で，主観的なしびれは変化がなく，客観的評価ツールで足底した触覚や振動覚の方が鋭敏に神経障害を反映しており，患者が障害を認知する前から感覚障害が生じていることが示唆された。公益社団法人 日本理学療法士協会, 2016年, 理学療法学Supplement, 2015, 1467 - 1467, 日本語
- 2016年, Cytogenetic and Genome Research, 150(3-4) (3-4), 287 - 292研究論文（学術雑誌）
- 2016年, Bone Marrow Transplantation, 51, S411Absolute Lymphocyte Count Recovery Predicts Clinical Outcome after Allogeneic Hematopoietic Stem Cell Transplantation in a Japanese Population[査読有り]
- 2016年, CYTOGENETIC AND GENOME RESEARCH, 149(3) (3), 165 - 170, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2016年, CYTOGENETIC AND GENOME RESEARCH, 150(3-4) (3-4), 287 - 292, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- Oxford University Press, 2016年, Japanese Journal of Clinical Oncology, 46(5) (5), 448 - 452, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2015年12月, INTERNATIONAL JOURNAL OF HEMATOLOGY, 102(6) (6), 713 - 718, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- Taylor and Francis Ltd, 2015年11月, Leukemia and Lymphoma, 56(11) (11), 3045 - 3051, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2015年11月, International journal of hematology, 102(5) (5), 643 - 643, 英語, 国内誌
- Springer-Verlag Tokyo, 2015年05月, International Journal of Hematology, 101(5) (5), 423 - 425, 英語, 国内誌研究論文（その他学術会議資料等）
- 2015年02月, 日本臨床, 73(増刊2 抗がん剤の副作用と支持療法) (増刊2 抗がん剤の副作用と支持療法), 139 - 142, 日本語【抗がん剤の副作用と支持療法-より適切な抗がん剤の安全使用をめざして-】 系統別抗がん剤の副作用 化学療法薬 アルキル化剤 副作用とその対策
- 2015年, Journal of Dental Research, 94(2) (2), 289 - 296
- 2015年, ACTA HAEMATOLOGICA, 134(2) (2), 76 - 79, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2015年, J Clin Exp Hematop, 55(3) (3), 181 - 5, 英語Coexistent t(8;21)(q22;q22) Translocation and 5q Deletion in Acute Myeloid Leukemia[査読有り]研究論文（学術雑誌）
- 2015年01月, ANNALS OF HEMATOLOGY, 94(1) (1), 177 - 179, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2015年, INTERNAL MEDICINE, 54(16) (16), 2057 - 2060, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- 2015年, INTERNAL MEDICINE, 54(22) (22), 2955 - 2955, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- (一社)日本血液学会-東京事務局, 2014年09月, 臨床血液, 55(9号) (9号), 1271 - 1271, 日本語肺、大腸重複癌に合併した自己免疫性溶血性貧血における自己抗体の標的分子の同定
- 2014年08月, ANNALS OF HEMATOLOGY, 93(8) (8), 1435 - 1438, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2014年03月, ANNALS OF HEMATOLOGY, 93(3) (3), 499 - 500, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2014年02月, Ann Hematol, 93(10) (10), 1791 - 3, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2014年, ACTA HAEMATOLOGICA, 132(2) (2), 244 - 246, 英語[査読有り]研究論文（学術雑誌）
- 2014年, INTERNAL MEDICINE, 53(1) (1), 73 - 74, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- 2014年, J Clin Exp Hematop, 54(2) (2), 167 - 70, 英語, 国内誌A new complex translocation t(8;11;21)(q22;q24;q22) in acute myeloid leukemia with RUNX1/RUNX1T1[査読有り]研究論文（学術雑誌）
- 2013年12月, Annals of Hematology, 92(12) (12), 1713 - 1715, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2013年09月, Leukemia and Lymphoma, 54(9) (9), 2055 - 2058, 英語[査読有り]研究論文（学術雑誌）
- 2013年08月, BMC Oral Health, 13(1) (1), 41 - 41, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2013年08月, American Journal of Hematology, 88(8) (8), 717 - 718, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2013年07月, INTERNATIONAL JOURNAL OF HEMATOLOGY, 98(1) (1), 6 - 7, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- 2013年03月, ANNALS OF HEMATOLOGY, 92(3) (3), 403 - 405, 英語[査読有り]研究論文（学術雑誌）
- 2013年02月, 日本医学放射線学会学術集会抄録集, (72回) (72回), S402, 日本語鼻腔原発NK/T細胞リンパ腫に対する放射線治療経験[査読有り]研究論文（その他学術会議資料等）
- 2013年02月, INTERNATIONAL JOURNAL OF HEMATOLOGY, 97(2) (2), 284 - 286, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- 2013年02月, DIAGNOSTIC PATHOLOGY, 8, 30 - 30, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- Gain of 11q by an additional ring chromosome 11 and trisomy 18 in CD5-positive intravascular large B-cell lymphomaChromosomal abnormalities of intravascular large B-cell lymphoma (IVLBCL), a rare form of extranodal diffuse large B-cell lymphoma, have been described in only a small number of cases. A 59-year-old female presented with pancytopenia and splenomegaly. Bone marrow was normocellular with 30.4% abnormal large lymphoid cells that were positive for CD5, CD19, CD20, HLA-DR and λ chain. Bone marrow biopsy showed intrasinusoidal infiltration of large lymphoid cells. G-banding and spectral karyotyping of the bone marrow cells demonstrated a complex karyotype as follows : 48,XX,-8,+r(11),+12,del(12)(p?) ×2,+18,der(19)(19?::p13 → qter),der(21)t(8;21)(q11.2;p11.2). Fluorescence in situ hybridization on interphase nuclei revealed three signals of CCND1 at 11q13, but two signals of BIRC3 at 11q22 and MLL at 11q23, indicating that r(11) contained CCND1. Together with other reported cases, our results indicate that the gain of 11q as well as trisomy 18 may be among the recurrent chromosomal aberrations in IVLBCL. Furthermore, an additional ring chromosome 11 could be a novel mechanism leading to the gain of 11q.2013年, J Clin Exp Hematop, 53(2) (2), 161 - 5, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- 2013年01月, LEUKEMIA, 27(1) (1), 233 - 235, 英語[査読有り]研究論文（学術雑誌）
- 2013年01月, Eur J Haematol, 90(1) (1), 59 - 67, 英語[査読有り]研究論文（学術雑誌）
- 2013年01月, EUROPEAN JOURNAL OF HAEMATOLOGY, 90(1) (1), 68 - 75, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2012年12月, LEUKEMIA RESEARCH, 36(12) (12), E218 - E221, 英語[査読有り]研究論文（学術雑誌）
- 2012年06月, EUROPEAN JOURNAL OF HAEMATOLOGY, 88(6) (6), 553 - 554, 英語[査読有り]研究論文（学術雑誌）
- 2012年06月, EUROPEAN JOURNAL OF HAEMATOLOGY, 88(6) (6), 553 - 554, 英語, 国際誌研究論文（学術雑誌）
- 2012年04月, LEUKEMIA RESEARCH, 36(4) (4), E84 - E86, 英語研究論文（学術雑誌）
- 2012年03月, EUROPEAN JOURNAL OF HAEMATOLOGY, 88(3) (3), 244 - 248, 英語, 国際誌研究論文（学術雑誌）
- 2012年, INTERNAL MEDICINE, 51(12) (12), 1579 - 1584, 英語[査読有り]研究論文（学術雑誌）
- 2011年11月, LEUKEMIA RESEARCH, 35(11) (11), E212 - E214, 英語研究論文（学術雑誌）
- 2011年09月, CANCER GENETICS, 204(9) (9), 501 - 506, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2011年09月, CANCER GENETICS, 204(9) (9), 501 - 506, 英語[査読有り]研究論文（学術雑誌）
- 2011年07月, LEUKEMIA RESEARCH, 35(7) (7), E100 - E103, 英語[査読有り]研究論文（学術雑誌）
- (一社)日本検査血液学会, 2011年06月, 日本検査血液学会雑誌, 12(学術集会) (学術集会), S79 - S79, 日本語NPM/RARαキメラ遺伝子を認めた急性前骨髄性白血病の一例
- 2011年06月, INTERNATIONAL JOURNAL OF HEMATOLOGY, 93(6) (6), 765 - 770, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- 2011年, INTERNAL MEDICINE, 50(24) (24), 3031 - 3035, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- 2011年, INTERNAL MEDICINE, 50(8) (8), 941 - 941, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- 2010年10月, MOLECULAR AND CELLULAR BIOLOGY, 30(20) (20), 4818 - 4827, 英語, 国際誌研究論文（学術雑誌）
- 2009年09月, INTERNATIONAL JOURNAL OF HEMATOLOGY, 90(2) (2), 217 - 225, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- 2009年03月, International Journal of Hematology, 89(2) (2), 195 - 200, 英語研究論文（学術雑誌）
- 2008年12月, INTERNATIONAL JOURNAL OF HEMATOLOGY, 88(5) (5), 536 - 542, 英語[査読有り]研究論文（学術雑誌）
- 2008年10月, International Journal of Hematology, 88(3) (3), 299 - 303, 英語研究論文（学術雑誌）
- 2008年, Internal Medicine, 47(15) (15), 1445 - 1446, 英語研究論文（学術雑誌）
- Developmental expression of EphB6 in the thymus: lessons from EphB6 knockout mice.A member of the largest family of receptor protein kinases, EphB6, lacks its intrinsic kinase activity, but it is expressed in normal human tissues. To investigate the physiological function of EphB6, we generated EphB6 deficient mice. EphB6(-/-) mice developed normally, revealed no abnormality in general appearance, and were fertile. Although a developmental increase of EphB6 in the fetal thymus was confirmed, T-cell development in various lymphoid organs of EphB6(-/-) mice was comparable to those of EphB6(+/+). Even in fetal thymus organ cultures, any developmental differences of EphB6(-/-) and EphB6(+/+) thymocytes were undetectable. The different binding characteristics to ephrin-Fc proteins between EphB6(-/-) and EphB6(+/+) thymocytes demonstrated that ephrin-B2 is the unique ligand for EphB6 among eight known ephrins. While EphB6 was a dominant receptor that binds to ephrin-B2 in adult thymocytes, fetal ones also expressed another EphB that binds to ephrin-B2. Overlapping expression of the EphB subfamily in the fetal thymus might compensate for the loss of EphB6 during the thymic development.2002年10月, Biochemical and biophysical research communications, 298(1) (1), 87 - 94, 英語, 国際誌研究論文（学術雑誌）
- 症例は44歳，男性。11年前に進行胃癌にて胃亜全摘術を施行されている。1996年2月，下腿，臀部に紫斑を認めたため近医を受診。高ALP血症，血小板減少を指摘され，当院に入院した。骨髄生検で骨髄内にムチン産生性の中分化型管状腺癌細胞がみられ，腺癌の骨髄転移と診断した。原発巣を検索したが残胃，大腸，前立腺等に病巣は認めず，11年前の胃癌の再発を疑った。microangiopathic hemolytic anemia, DICを合併しており，抗凝固療法による治療を行ったが改善は得られなかった。その後，肺の癌性リンパ管症による呼吸不全にて死亡した。剖検では残胃の胃粘膜に再発はみられなかったが，残胃のリンパ管内の一部に腺癌細胞が認められ，11年前の胃癌の転移と考えた。11年もの長期にわたり，なぜ残胃のリンパ管内および骨髄に腺癌細胞が顕在化せず潜んでいたかは不明である。一般社団法人 日本血液学会, 1998年09月, 臨床血液, 39(9) (9), 670 - 675, 日本語
- Academic Press Inc., 1997年06月, Biochemical and Biophysical Research Communications, 235(3) (3), 487 - 492, 英語研究論文（学術雑誌）
- (一社)日本医療検査科学会, 2025年08月, 医療検査と自動化, 50(4) (4), 281 - 281, 日本語自動搬送ラインを活用した検体処理プロセスの安定性評価とバイオリソース提供における品質担保
- (一社)日本医療検査科学会, 2025年08月, 医療検査と自動化, 50(4) (4), 283 - 283, 日本語病院併設型バイオバンクにおける全血残余検体の収集・提供体制の評価
- (一社)日本臨床検査医学会, 2025年07月, 日本臨床検査医学会誌, 73(補冊) (補冊), 206 - 206, 日本語Fib4 indexは関節リウマチ患者においてMTX継続率を予想する
- (一社)日本リウマチ学会, 2025年03月, 日本リウマチ学会総会・学術集会プログラム・抄録集, 69回, 511 - 511, 日本語関節リウマチの治療:DMARDs・NSAIDs・その他1 Fib-4 indexは関節リウマチ患者のメトトレキサート治療において中断のリスク因子となる
- 2025年, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 47thPerformance statusはSOS/VODの病勢進行予測に有用である
- (一社)日本臨床衛生検査技師会, 2024年10月, 医学検査, 73(4) (4), 644 - 651, 日本語当院における採血管内凝固検体を除外する運用手順の検証
- (一社)日本血液学会, 2024年10月, 日本血液学会学術集会, 86回, O2 - 3, 英語日常的に計算可能な臨床的指標と、類洞閉塞症候群(SOS/VOD)の病勢進行との関連
- (一社)日本血液学会, 2024年10月, 日本血液学会学術集会, 86回, O2 - 4, 英語B細胞リンパ腫に対するマクロファージ標的療法のヒト化マウスモデルを用いた前臨床評価
- (一社)日本臨床検査医学会, 2024年10月, 日本臨床検査医学会誌, 72(補冊) (補冊), 201 - 201, 日本語
- 2024年, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 46th類洞閉塞症候群の新改訂EBMT診断基準の有用性
- (株)メディカルドゥ, 2024年01月, 遺伝子医学, 14(1) (1), 40 - 46, 日本語【ゲノム医療におけるバイオバンクの役割とその利活用】ニーズドリブン型バイオリソースセンターの取り組み 実績と課題,ならびに発展型の考察
- (一社)日本血液学会, 2023年10月, 日本血液学会学術集会, 85回, 683 - 683, 英語血小板輸血不応の項を含む新診断基準による、類洞閉塞症候群(SOS)の早期診断
- (株)医学書院, 2023年04月, 耳鼻咽喉科・頭頸部外科, 95(5) (5), 321 - 324, 日本語
- (一社)日本病院総合診療医学会, 2023年02月, 日本病院総合診療医学会雑誌, 19(臨増1) (臨増1), 236 - 236, 日本語リンパ腫維持療法中に発症したCOVID-19罹患後の間質性肺疾患に対して,少量ステロイド療法が著効した一例
- (一社)日本臨床検査医学会, 2022年10月, 日本臨床検査医学会誌, 70(補冊) (補冊), 203 - 203, 日本語
- (一社)日本臨床衛生検査技師会, 2022年05月, 日本医学検査学会抄録集, 71回, 474 - 474, 日本語バイオリソースセンター業務における臨床検査技師の役割
- (一社)日本臨床衛生検査技師会, 2022年05月, 日本医学検査学会抄録集, 71回, 475 - 475, 日本語神戸大学医学部附属病院バイオリソースセンターにおけるバイオバンクシステムの構築
- 2022年, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 44th同種造血幹細胞移植後患者に対するSARS-CoV-2ワクチンの安全性と有効性
- (一社)日本癌学会, 2021年09月, 日本癌学会総会記事, 80回, [J17 - 4], 英語GSK3阻害剤は、複数の薬剤耐性を1剤で克服し、初代AML細胞に対してゲムツズマブオゾガマイシンによる細胞死を増強する
- (一社)日本血液学会, 2021年09月, 日本血液学会学術集会, 83回, PS - 7, 英語NRAS c.38G>A変異により発症したRARAの相互転座を伴わない急性前骨髄球性白血病(Novel NRAS c.38G>A mutation causes RARA translocation negative acute promyelocytic-like leukemia)
- (一社)日本血液学会, 2021年09月, 日本血液学会学術集会, 83回, PS - 2, 英語新たなKMT2A/EPS15融合遺伝子発現とt(1;11)(p32;q23)転座を認めたFLT3変異陽性B細胞性急性リンパ性白血病(Expression of a novel KMT2A/EPS15 fusion gene in FLT3 mutation-positive B-ALL with t(1;11)(p32;q23))
- (一社)日本血液学会, 2021年09月, 日本血液学会学術集会, 83回, PS - 6, 英語慢性GVHDに対する肝移植後の一過性末梢血マクロキメリズム(Transient macrochimerism following a liver transplant for hepatic GVHD after an allo-PBSCT)
- (一社)日本血液学会, 2021年09月, 日本血液学会学術集会, 83回, OS2 - 4, 英語自家造血幹細胞移植患者におけるsynbiotics投与の有効性についての臨床試験(Efficacy of synbiotics in auto-PBSCT patients: a prospective, double-blind, placebo-controlled trial)
- (一社)日本血液学会, 2021年09月, 日本血液学会学術集会, 83回, OS3 - 5, 英語同種移植におけるflash sensor-based glucose monitoringの安全性の検討(Safety and accuracy of flash sensor-based glucose monitoring devise in patients after Allo-HSCT)
- 2020年, 日本造血細胞移植学会総会プログラム・抄録集, 42ndT細胞性リンパ芽球性リンパ腫/白血病の再発とドナー細胞由来白血病の鑑別を要した一例
- 2020年, 日本血液学会学術集会抄録(Web), 82ndSorafenibによる加療を行ったFLT3-ITD陽性急性骨髄性白血病と甲状腺乳頭がんの合併例
- 2020年, 日本血液学会学術集会抄録(Web), 82nd日本人悪性腫瘍関連静脈血栓塞栓症に対するapixaban療法の第II相臨床試験
- (一社)日本内科学会, 2020年, 日本内科学会雑誌, 109(Suppl.) (Suppl.), 258 - 258, 日本語リソソーム機能活性化を介した抗体薬物複合体であるゲムツズマブオゾガマイシンの殺細胞効果増強法
- 2019年, 日本造血細胞移植学会総会プログラム・抄録集, 41st筋炎症状で発症した節外性NK/T細胞リンパ腫
- (一社)日本癌学会, 2019年, 日本癌学会学術総会抄録集(Web), 78th, P - 3177, 英語mTORC1/2阻害剤AZD2014は,初代AML細胞に対してゲムツズマブオゾガマイシンによる細胞死を増強する
- (一社)日本血液学会-東京事務局, 2018年09月, 臨床血液, 59(9) (9), 1641 - 1641, 英語sorafenib投薬を中断することで顕在化したFLT3-ITD陽性急性骨髄性白血病の一例(Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive acute myeloid leukemia)
- 2018年03月, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(3) (3), S285 - S286, 英語Pharmacokinetics of Intravenous Mycophenolate Mofetil after Hematopoietic Stem Cell Transplantation in Japanese Population研究発表ペーパー・要旨（国際会議）
- 2018年, 日本分子生物学会年会プログラム・要旨集(Web), 41st, ROMBUNNO.3LBA‐115 (WEB ONLY), 英語リソソーム機能を介したAMLに対する新規治療戦略
- (一社)日本血栓止血学会, 2017年04月, 日本血栓止血学会誌, 28(2) (2), 233 - 233, 日本語デフェラシロックスは急性肺傷害モデルマウスの好中球細胞外トラップを抑制する
- 2017年, 臨床血液, 58(9) (9)神戸大学医学部附属病院での悪性リンパ腫に対するESHAPレジメンの後方視的分析
- 2017年, 日本造血細胞移植学会総会プログラム・抄録集, 39th難治性の口唇慢性GVHDに対して湿潤療法が著効した一例
- 2017年, 日本臨床腫瘍学会学術集会(CD-ROM), 15th同種造血幹細胞移植前にルキソリチニブを使用した原発性骨髄線維症の一例
- 2017年, 日本造血細胞移植学会総会プログラム・抄録集, 40th非血縁者間骨髄移植前の病勢コントロールとしてGCD療法が有効であった肝脾原発T細胞性リンパ腫の一例
- 2017年, 日本造血細胞移植学会総会プログラム・抄録集, 40th同種造血幹細胞移植の経過中に集中治療を要した患者の検討
- 2017年, 日本造血細胞移植学会総会プログラム・抄録集, 40th血縁ドナーにおける血液成分分離装置Spectra OptiaとCOBE Spectraの採取データの比較検討
- 2017年, 日本造血細胞移植学会総会プログラム・抄録集, 40th自家末梢血幹細胞移植における栄養状態と予後に関する後方視的解析
- 2016年07月01日, ANNALS OF ONCOLOGY, 27, 英語NANOG expression as a responsive biomarker during treatment with Hedgehog signal inhibitor in acute myeloid leukemia研究発表ペーパー・要旨（国際会議）
- (一社)日本血栓止血学会, 2016年05月, 日本血栓止血学会誌, 27(2) (2), 235 - 235, 日本語感染症肺障害モデルマウスを用いた活性化好中球の形態観察
- (公社)日本医学放射線学会, 2016年02月, Japanese Journal of Radiology, 34(Suppl.) (Suppl.), 49 - 49, 日本語当院におけるゼヴァリンの初期経験[査読有り]会議報告等
- 2016年, 臨床血液, 57(9) (9)CHOPレジメンによる治療を受けた悪性リンパ腫患者におけるパロノセトロンの鎮吐作用
- 2016年, 日本造血細胞移植学会総会プログラム・抄録集, 38th自律神経ストームを伴った造血幹細胞移植後HHV-6脳炎
- 2016年, 日本造血細胞移植学会総会プログラム・抄録集, 38th自家移植後の再発・骨髄不全に対し,同種骨髄移植が有効であった原発性マクログロブリン血症
- 2016年, 日本臨床腫瘍学会学術集会(CD-ROM), 14th造血器悪性腫瘍に対する化学療法中のD-indexと口腔内感染性合併症との関連についての検討
- 2015年12月03日, BLOOD, 126(23) (23), 英語Biomarker and Gene Profiling Analyses in Acute Myeloid Leukemia during Treatment with Hedgehog Signaling Inhibitor研究発表ペーパー・要旨（国際会議）
- 2015年11月, ANNALS OF ONCOLOGY, 26, 89 - 89, 英語Biomarker and gene profiling analyses in acute myeloid leukemia during treatment with Hedgehog signaling inhibitor研究発表ペーパー・要旨（国際会議）
- (一社)日本血液学会-東京事務局, 2015年11月, 臨床血液, 56(11号) (11号), 2377 - 2377, 日本語30年来頸部腫瘤を有する患者より発症したDouble-hit lymphoma(DHL)の1例[査読有り]会議報告等
- 2015年02月, 日本内科学会雑誌, 104(Suppl.) (Suppl.), 241, 日本語化学療法中の固形腫瘍患者に対するインフルエンザワクチン2回接種法の有効性と安全性[査読有り]会議報告等
- 2015年, 臨床血液, 56(9) (9)t(12;17)(p13;q21)/TAF15-ZNF384及びder(1;18)(q10;q10)の混合形質性急性白血病
- 2014年12月, BLOOD, 124(21) (21), 英語Efficacy of the Two-Dose Influenza Vaccine in Cancer Patients Receiving Chemotherapy: A Prospective Study研究発表ペーパー・要旨（国際会議）
- (一社)日本血液学会-東京事務局, 2014年11月, 臨床血液, 55(11号) (11号), 2339 - 2339, 日本語腹部DLBCL病変出現1ヵ月前に発症したNeurolymphomatosisの1例会議報告等
- (一社)日本癌学会, 2014年09月, 日本癌学会総会記事, 73回(73回) (73回), P - 2060, 日本語NK細胞浸潤がヒト乳がん異種移植マウスの腫瘍増殖に与える影響(Effect of natural killer cell infiltration on the growth of the mouse xenografts tumors of human breast cancers)(英語)[査読有り]会議報告等
- 2014年04月, 日本皮膚科学会雑誌, 124(5号) (5号), 974, 日本語多発筋炎の加療中に生じたMycobacterium haemophilum感染症の1例[査読有り]会議報告等
- 2014年, 臨床血液, 55(9) (9)2例の急性骨髄性白血病の二重微小染色体の形のMYC増幅
- 2014年, 日本造血細胞移植学会総会プログラム・抄録集, 36th急性GVHD予防薬ミコフェノール酸モフェチルを用いた同種造血幹細胞移植100例報告
- 2014年, 日本臨床腫瘍学会学術集会(CD-ROM), 12th気道狭窄を伴う異なる頸部悪性腫瘍の2例
- (一社)日本頭頸部癌学会, 2013年05月, 頭頸部癌, 39(2号) (2号), 237 - 237, 日本語甲状腺原発MALTリンパ腫の治療経験会議報告等
- (一社)日本糖尿病学会, 2013年02月, 糖尿病, 56(2) (2), 128 - 128, 日本語チロシンキナーゼ阻害剤による耐糖能悪化が疑われた慢性骨髄性白血病の1例
- 2013年, 臨床血液, 54(9) (9)原発性心臓中間型Burkitt/びまん性大細胞B細胞リンパ腫の1症例
- 2013年, 日本造血細胞移植学会総会プログラム・抄録集, 35th同種骨髄移植後の類洞閉塞症候群に伴う難治性体液貯留に対するトルバプタンの使用経験
- 2012年10月, ANNALS OF ONCOLOGY, 23, 161 - 161, 英語DACARBAZINE MONO-THERAPY FOR UNRESECTABLE NEUROENDOCRINE TUMOR: A RETROSPECTIVE ANALYSIS研究発表ペーパー・要旨（国際会議）
- 2012年09月, LEUKEMIA RESEARCH, 36(9) (9), E202 - E205, 英語[査読有り]速報，短報，研究ノート等（学術雑誌）
- 2012年02月, 日本内科学会雑誌, 101(Suppl.) (Suppl.), 174, 日本語切除不能高分化神経内分泌腫瘍に対するダカルバジン療法[査読有り]会議報告等
- 2012年, 臨床血液, 53(9) (9)t(7;9)(q34;q34)を伴ったT細胞リンパ芽球性リンパ腫の新規なTRB@NOTCH1融合遺伝子
- 2012年, 日本造血細胞移植学会総会プログラム・抄録集, 34thImatinib単独投与後に臍帯血移植を行ったCML myeloid blast-crisis
- 2012年, 日本造血細胞移植学会総会プログラム・抄録集, 34th造血幹細胞移植前の眼科受診の意義
- 2012年, 日本造血細胞移植学会総会プログラム・抄録集, 34thSMILE療法及び末梢血幹細胞移植によって良好な経過が得られた再発・難治性NK/T細胞リンパ腫の一例
- (一社)日本血液学会-東京事務局, 2012年01月, 臨床血液, 53(1) (1), 118 - 119, 日本語SMILE療法及び同種骨髄移植によって良好な経過が得られた再発・難治性NK/T細胞リンパ腫の1例
- 2012年, INTERNAL MEDICINE, 51(12) (12), 1579 - 1584, 英語, 国内誌[査読有り]
- 2011年, 臨床血液, 52(9) (9)赤血球低形成と好塩基球増加症を伴う骨髄異形成症候群の同腕染色体17q
- 2011年, 日本造血細胞移植学会総会プログラム・抄録集, 33rd急性GVHD予防薬ミコフェノール酸モフェチル(MMF)使用下における移植後G-CSF至適投与量の検討
- 2011年, 日本造血細胞移植学会総会プログラム・抄録集, 33rd臍帯血移植前にボリコナゾール水晶体内投与が有効であった真菌性眼内炎
- 2010年12月, 日本生化学会大会・日本分子生物学会年会合同大会講演要旨集83回・33回, 1P - 0662, 日本語間質細胞のメディエーターサブユニットMED1/TRAP220はオステオポンチン発現を介する造血幹細胞/前駆細胞の支持に関与する(Mediator subunit MED1/TRAP220 in stromal cells is involved in hematopoietic stem/progenitor cell support through osteopontin expression)(英語)[査読有り]会議報告等
- (一社)日本腎臓学会, 2010年08月, 日本腎臓学会誌, 52(6) (6), 826 - 826, 日本語両腎への形質細胞腫浸潤により腎機能低下を認めた一例
- 和歌山医学会, 2009年12月, 和歌山医学, 60(4) (4), 160 - 160, 日本語
- (一社)日本血液学会-東京事務局, 2009年09月, 臨床血液, 50(9) (9), 933 - 933, 日本語再発・難治性AMLに対するCAG療法およびG-CSF先行ゲムツズマブオゾガマイシン(GO)療法
- (一社)日本血液学会-東京事務局, 2009年09月, 臨床血液, 50(9) (9), 1127 - 1127, 日本語縦隔原発胚細胞性腫瘍 血液悪性腫瘍症候群の1例
- (一社)日本リンパ網内系学会, 2009年06月, 日本リンパ網内系学会会誌, 49, 107 - 107, 日本語
- 2009年04月, International Journal of Hematology, 89(3) (3), 400 - 402, 英語速報，短報，研究ノート等（学術雑誌）
- (一社)日本血液学会-東京事務局, 2008年09月, 臨床血液, 49(9) (9), 947 - 947, 日本語複雑なC-MYC転座を示すCD5陽性大細胞型Bリンパ腫細胞株の樹立
- (一社)日本血液学会-東京事務局, 2008年09月, 臨床血液, 49(9) (9), 1002 - 1002, 日本語M-CSFやデシタビンはU937細胞に対するゲムツズマブ・オゾガマイシンの殺細胞効果を増強する
- (一社)日本血液学会-東京事務局, 2008年09月, 臨床血液, 49(9) (9), 1192 - 1192, 日本語Liposomal doxorubicinにより血球貪食症候群が改善した後天性免疫不全症候群の一例
- (一社)日本血液学会-東京事務局, 2007年09月, 臨床血液, 48(9) (9), 877 - 877, 日本語当科におけるゲムツズマブオゾガマイシンの投与症例から、難治性AMLに対する至適な投与方法を考察する
- (一社)日本血液学会-東京事務局, 2007年09月, 臨床血液, 48(9) (9), 1150 - 1150, 日本語Rituximab投与後速やかに臨床症状の改善を認めた血栓性血小板減少性紫斑病の一例
- (一社)日本血液学会-東京事務局, 2007年09月, 臨床血液, 48(9) (9), 1190 - 1190, 日本語メソトレキセート(MTX)中止により自然消退したEBV関連Bリンパ増殖性疾患
- (一社)日本血液学会-東京事務局, 2006年09月, 臨床血液, 47(9) (9), 1153 - 1153, 日本語EphB6受容体はリガンド濃度依存的に二相性に細胞接着、細胞移動を調節する
- (一社)日本血液学会-東京事務局, 2006年09月, 臨床血液, 47(9) (9), 1254 - 1254, 日本語同種末梢血幹細胞移植後に重症心不全をきたした難治性急性骨髄性白血病の一例
- (一社)日本血液学会, 2001年03月, International Journal of Hematology, 73(Suppl.1) (Suppl.1), 141 - 141, 日本語ヒト白血病細胞株におけるEphB6受容体特異的リガンドの検索(Identification of a Ligand for EphB6 expressed in human leukemia cell lines)
- (一社)日本血液学会-東京事務局, 1999年09月, 臨床血液, 40(9) (9), 923 - 923, 日本語当科における造血器悪性腫瘍に対する自家末梢血CD34陽性細胞選択的採取及び移植の経験
- (一社)日本血液学会-東京事務局, 1998年10月, 臨床血液, 39(10) (10), 1060 - 1060, 日本語活性型ビタミンD3(aVitD3)大量投与にも拘わらず高Ca血症をきたさなかったM4,M5の4例
- (一社)日本血液学会-東京事務局, 1998年10月, 臨床血液, 39(10) (10), 1066 - 1066, 日本語自家末梢血CD34陽性細胞移植後に特発性間質性肺炎(IIP)をきたした高齢者ALLの1例
- 共著, 羊土社, 2022年07月, 日本語, ISBN: 9784758123921関節リウマチ関連リンパ増殖性疾患の診断と管理の手引き
- その他, 南江堂, 2017年06月, 日本語抗悪性腫瘍薬コンサルトブック 「薬理学的特性に基づく治療」 / 抗体薬「12 ゲムツズマブオゾガマイシン」「13 イブリツモマブチウキセタン」学術書
- 分担執筆, 抗がん薬-アルキル化剤, 南江堂, 2012年12月, 日本語, ISBN: 9784524269679新臨床腫瘍学 : がん薬物療法専門医のために
- 第66回日本生化学会近畿支部例会, 2019年05月, 英語, 京都, 国内会議高齢PKN1キナーゼネガティブノックインマウスは、高齢PKN1ノックアウトマウスと異なった表現型を示す口頭発表（一般）
- 第41回日本造血細胞移植学会総会, 2019年03月, 日本語, 日本造血細胞移植学会, 大阪, 国内会議筋炎症状で発症した節外性NK/T細胞リンパ腫ポスター発表
- 第41回日本造血細胞移植学会総会, 2019年03月, 日本語, 日本造血細胞移植学会, 大阪, 国内会議ポナチニブ投与後に遅発性類洞閉塞症候群を発症した一例ポスター発表
- 第223回日本内科学会近畿地方会, 2019年03月, 日本語, 日本内科学会, 京都, 国内会議ステロイド軟膏の使用中止後に相対的副腎不全をきたした1例口頭発表（一般）
- 第223回日本内科学会近畿地方会, 2019年03月, 日本語, 日本内科学会, 京都, 国内会議EBV関連 sequential lymphomaの1例口頭発表（一般）
- 第1回日本腫瘍循環器学会学術集会, 2018年11月, 日本語, 日本腫瘍循環器学会, 東京, 国内会議悪性腫瘍関連静脈血栓寒栓症に対する包括的研究：J-CAV project in progress口頭発表（一般）
- 第110回近畿血液学地方会, 2018年11月, 日本語, 日本血液学会, 奈良, 国内会議PET/MRI陰性だが頭部造影MRIにて中枢神経浸潤が明らかとなった精巣原発DLBCLの一例口頭発表（一般）
- APBMT, 2018年11月, 英語, アジア太平洋骨髄移植学会, Taipei, 国際会議Nutrition and Rehabilitation of Hematopoietic Stem Cell Transplantation Patientsポスター発表
- 第80回日本血液学会学術集会, 2018年10月, 日本語, 日本血液学会, 大阪, 国内会議多発性筋炎様症状を呈したNK/T細胞リンパ腫ポスター発表
- 第80回日本血液学会学術集会, 2018年10月, 日本語, 日本血液学会, 大阪, 国内会議新たなZMYND11/MBTD1融合遺伝子の発現とt(10;17)(p15;q21)転座を認めたCD7+CD56+急性骨髄性白血病ポスター発表
- 第80回日本血液学会学術集会, 2018年10月, 日本語, 日本血液学会, 大阪, 国内会議シクロスポリン療法後の骨髄移植にて重症肝類洞閉塞症候群をきたした一例ポスター発表
- 第80回日本血液学会学術集会, 2018年10月, 日本語, 日本血液学会, 大阪, 国内会議TLR9の一塩基多型により無症候性CMV感染症を呈した再生不良性貧血の一例.ポスター発表
- 第80回日本血液学会学術集会, 2018年10月, 英語, 日本血液学会, 大阪, 国内会議Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive actute myeloid leukemia.ポスター発表
- 第80回日本血液学会学術集会, 2018年10月, 英語, 日本血液学会, 大阪, 国内会議Aplastic anemia that developed asymptomatic CMV infection due to a single nucleotide polymorphism of TLR9ポスター発表
- 第19回日本検査血液学会学術集会, 2018年07月, 日本語, 大宮, 国内会議慢性好塩基球性白血病から急性骨髄性白血病へと進展した一症例口頭発表（一般）
- 第16回日本臨床腫瘍学会, 2018年07月, 英語, 日本臨床腫瘍学会, 神戸, 国内会議Synchronous esophageal cancer and multiple myeloma: a report of two casesポスター発表
- 第16回日本臨床腫瘍学会, 2018年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議Flow cytometric measurement of erythrocyte membrane-bound IgG: A potential diagnostic method for colorectal cancerポスター発表
- 第62回 日本リウマチ学会総会・学術集会, 2018年04月, 日本語, 日本リウマチ学会, 東京, 国内会議リウマチ患者に発生するリンパ増殖性疾患に対する血液内科的マネジメント 診断、経過観察、化学療法、予後などに関して[招待有り]シンポジウム・ワークショップパネル（指名）
- Aemrican Association for Cancer Research Annual Meeting 2018, 2018年04月, 英語, American Association for Cancer Research, シカゴ, 国際会議Flow cytometric measurement of erythrocyte membrane-bound IgG: A potential diagnostic method for colorectal cancerポスター発表
- 第40回日本造血細胞移植学会総会, 2018年02月, 日本語, 日本造血細胞移植学会, 札幌, 国内会議非血縁者間骨髄移植前の病勢コントロールとしてGCD療法が有効であった肝脾原発T細胞性リンパ腫の一例ポスター発表
- 第40回日本造血細胞移植学会総会, 2018年02月, 日本語, 日本造血細胞移植学会, 札幌, 国内会議同種造血幹細胞移植の経過中に集中治療を要した患者の検討口頭発表（一般）
- 第40回日本造血細胞移植学会総会, 2018年02月, 日本語, 日本造血細胞移植学会, 札幌, 国内会議造血幹細胞移植病棟における疑義照会の後方視的検討口頭発表（一般）
- 第40回日本造血細胞移植学会総会, 2018年02月, 日本語, 日本造血細胞移植学会, 札幌, 国内会議自家末梢血幹細胞移植における栄養状態と予後に関する方視的解析ポスター発表
- 第40回日本造血細胞移植学会総会, 2018年02月, 日本語, 日本造血細胞移植学会, 札幌, 国内会議血縁ドナーにおける血液成分分離装置Spectra OptiaとCOBE Spectraの採取データの比較検討ポスター発表
- ASBMT/CIBMTR tandem meetings 2018, 2018年02月, 英語, ASBMT/CIBMTR, Salt Lake City, USA, 国際会議Pharmacokinetics of intravenous mycophenolate mofetil after hematopoietic stem cell transplantation in Japanese populationポスター発表
- 第40回日本造血細胞移植学会総会, 2018年02月, 日本語, 日本造血細胞移植学会, 札幌, 国内会議Pharmacokinetics of intravenous mycophenolate mofetil after cord blood transplantation in Japanese口頭発表（一般）
- 59th American Society of Hematology Annual Meeting and Exposition, 2017年12月, 英語, American Society of Hematology, Atlanta , GA, USA, 国際会議An mTORC1/2 Kinase Inhibitor Remarkably Enhances the Cytotoxicity of Gemtuzumab Ozogamicin By Activating Lysosomal Function and Cell Cycle Promotion in AML Cellsポスター発表
- 第79回日本血液学会学術集会, 2017年10月, 日本語, 日本血液学会, 東京, 国内会議Retrospective analysis of TLS risk in lymphoma patients stratified by cholinesterase levelポスター発表
- 第79回日本血液学会学術集会, 2017年10月, 英語, 日本血液学会, 東京, 国内会議Retrospective analysis of the ESHAP regimen for malignant lymphoma in Kobe University Hospital.ポスター発表
- 第79回日本血液学会学術集会, 2017年10月, 日本語, 日本血液学会, 東京, 国内会議MYC amplification in the form of ring chromosomes 8 in acute myeloid leukemia with t(11;16)(q13;p11)ポスター発表
- 第76回日本癌学会学術集会, 2017年09月, 日本語, 日本癌学会, 神奈川（横浜）, 国内会議c-Kit遺伝子変異細胞株においてmicroRNA-7はRB1発現を抑制し染色体不安定性をもたらすポスター発表
- 10th International Conference on HHV-6&7, 2017年07月, 英語, 10th International Conference on HHV-6&7, ベルリン, ドイツ, 国際会議Expression of CD134(OX40) on T cells is a trigger of human herpesvirus 6B reactivation and replication after hematopoietic cell transplantationポスター発表
- 第15回日本臨床腫瘍学会学術集会, 2017年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議Establishment and Gene Expression Analysis of a Double-Hit Lymphoma Cell Lineポスター発表
- 第107回近畿血液学地方会, 2017年06月, 日本語, 日本血液学会, 京都, 国内会議慢性C型肝炎治療後に発症したB細胞性前リンパ球性白血病の一例口頭発表（一般）
- 第31回ヘルペスウイルス研究会, 2017年06月, 日本語, 第31回ヘルペスウイルス研究会, 松江, 国内会議造血幹細胞移植後のT細胞におけるCD134(OX40）の発現が、移植後HHV-6B再活性化および増殖の誘因となる口頭発表（一般）
- Annual Meeting of the American Association for Cancer Research 2017, 2017年04月, 英語, American Asociation for Cancer Research, Washington DC, USA, 国際会議MicroRNA-7 suppresses RB1 expression leading to chromosomal instability in leukemia cells harboring c-Kit mutationポスター発表
- 第39回日本造血細胞移植学会, 2017年03月, 日本語, 日本造血細胞移植学会, 島根, 国内会議難治性の口唇慢性GVHDに対して湿潤療法が著効した一例ポスター発表
- 第39回日本造血細胞移植学会総会, 2017年03月, 日本語, 日本造血細胞移植学会, 松江, 国内会議肝中心静脈閉塞症（VOD）モデルマウスを用いた肝静脈閉塞への好中球細胞外トラップ（NETs）関与の可能性口頭発表（一般）
- 第39回日本造血細胞移植学会総会, 2017年03月, 日本語, 日本造血細胞移植学会, 松江, 国内会議シクロスポリンAが自家末梢血幹細胞移植後の再発に有効であった皮膚γδＴ細胞リンパ腫の一例ポスター発表
- 第78回日本血液学会学術集会, 2016年10月, 日本語, 日本血液学会, 横浜, 国内会議The antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimenポスター発表
- 第78回日本血液学会総会, 2016年10月, 日本語, 日本血液学会, 横浜, 国内会議Ph陽性慢性骨髄性白血病にみられた先天的バーキット様相互転座ｔ（8；22）（ｑ24；ｑ11．2）ポスター発表
- 第78回 日本血液学会総会, 2016年10月, 日本語, 日本血液学会, 横浜, 国内会議Mycophenolate mofetil for GVHD prophylaxis might not favor the development of engraftment syndrome.ポスター発表
- 第78回日本血液学会学術集会, 2016年10月, 日本語, 日本血液学会, 横浜市, 国内会議Coexpression of NUP98/TOP1 and TOP1/NUP98 in de novo AML with t(11;20)(p15;q12) and t(2;5)(q33;q31)ポスター発表
- 第78回 日本血液学会総会, 2016年10月, 日本語, 日本血液学会, 横浜, 国内会議BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia .ポスター発表
- The 21st Annual Congress of Asia Pacific Blood and Marrow Transplantation Group 2016, 2016年10月, 英語, Asia-Pacific Blood and Marrow Transplantation Group, Singapore, Singapore, 国際会議A REDUCED INTENSITY CONDITIONING REGIMEN USING FLUDARABINE AND BUSULFAN (FLU-BU2)ポスター発表
- 第213回日本内科学会近畿地方会, 2016年09月, 日本語, 日本内科学会, 大阪, 国内会議リンパ節生検で完全梗塞が認められ診断に難渋したホジキンリンパ腫の1例口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議発熱性好中球減少症における質量分析を用いた菌種同定の有用性についての検討口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議同種造血幹細胞移植後のリンパ球回復と予後に関する後方視的解析口頭発表（一般）
- 第14回日本臨床腫瘍学会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸市, 国内会議造血器悪性腫瘍に対する化学療法中のD-indexと口腔内感染性合併症との関連についての検討口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議急性骨髄性白血病に対するヘッジホッグ阻害薬投与の治療反応性バイオマーカーとしてのNANOG発現口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議肝移植後のリンパ増殖性疾患に対する治療戦略口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 英語, 日本臨床腫瘍学会, 神戸, 国内会議Treatment strategies for double primary neoplasm patients who develop malignant lymphoma and solid tumors口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議Quick detection of bacteria with mass spectrometry might reduce mortality in ferile neutropenia口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議Mycophenolate Mofetilを使用した造血幹細胞移植後に発症したHHV-6脳炎の治療経過口頭発表（一般）
- 7th, JSH International Symposium, 2016年05月, 英語, 日本血液学会, Awaji, Japan, 国際会議Delayed Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation with Mycophenolate Mofetilポスター発表
- 42nd, Annual Meeting of the European Society for Blood and Marrow Transplantation, 2016年04月, 英語, European Society for Blood and Marrow Transplantation, Valencia, Spain, 国際会議Absolute Lymphocyte Count Recovery Predicts Clinical Outcome after Allogeneic Hematopoietic Stem Cell Transplantation in a Japanese Populationポスター発表
- 第38回日本造血幹細胞移植学会総会, 2016年03月, 日本語, 日本造血細胞移植学会, 名古屋, 国内会議自律神経ストームを伴った造血幹細胞移植後HHV-6脳炎口頭発表（一般）
- 57th ASH Annual Meeting, 2015年12月, 英語, ASH, オーランド, アメリカ, 国際会議Biomarker and Gene Profiling Analyses in Acute Myeloid Leukemia during Treatment with Hedgehog Signaling Inhibitor.口頭発表（一般）
- 第210回日本内科学会近畿地方, 2015年11月, 日本語, 日本内科学会, 神戸, 国内会議超高齢で発症した発作性夜間血色素尿症の1例。口頭発表（一般）
- 第210回日本内科学会近畿地方, 2015年11月, 日本語, 日本内科学会, 神戸, 国内会議診断に難渋したhairy cell leukemiaの一例。口頭発表（一般）
- 第210回日本内科学会近畿地方, 2015年11月, 日本語, 日本内科学会, 神戸, 国内会議30年来頚部腫瘤を有する患者より発症したDouble-hit lymphoma(DHL)の1例口頭発表（一般）
- 第77回日本血液学会学術集会, 2015年10月, 英語, 日本血液学会, 金沢, 国内会議Mixed phenotype acute leukemia with t(12;17)(p13;q21)/TAF15-ZNF384 and der(1;18)(q10;q10)ポスター発表
- 第20回アジア太平洋造血細胞移植学会年次学術集会, 2015年10月, 英語, アジア太平洋造血細胞移植学会, 沖縄, 国際会議Herpesvirus 6 Encephalitis after Hematopoietic Stem Cell Transplantation with Administration of Mycophenolate Mofetil for Graft-versus-host Disease Prophylaxis in Japan: a Single Institution Experience.ポスター発表
- 第77回日本血液学会学術集会, 2015年10月, 英語, 日本血液学会, 金沢, 国内会議Biomarker and gene profiling analyses in acute myeloid leukemia during treatment with Hedgehog signaling inhibitor口頭発表（一般）
- 第77回日本血液学会学術集会, 2015年10月, 英語, 日本血液学会, 金沢, 国内会議A case of scopulariopsis pneumonia with acute myeloid leukemiaポスター発表
- 第77回日本血液学会学術集会, 2015年10月, 英語, 日本血液学会, 金沢, 国内会議A case of myeloid sarcoma with myelofibrosis secondary to polycthemia veraポスター発表
- 第209回日本内科学会近畿地方会, 2015年09月, 日本語, 日本内科学会, 大阪, 国内会議血球貪食症候群を合併した脾臓原発びまん性大細胞型B細胞リンパ腫(DLBCL)の1例口頭発表（一般）
- 第13回日本臨床腫瘍学会学術集会, 2015年07月, 英語, 日本臨床腫瘍学会, 札幌, 国内会議Biomarker and gene profiling analyses in acute myeloid leukemia during treatment with Hedgehog signaling inhibitor口頭発表（一般）
- the 6th JSH International Symposium, 2015年05月, 英語, 日本血液学会, 軽井沢, 国内会議Absolute Lymphocyte Count Recovery Predicts Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantationポスター発表
- 第112回日本内科学会総会, 2015年04月, 日本語, 日本内科学会, 京都, 国内会議化学療法中の固形腫瘍患者に対するインフルエンザワクチン2回接種法の有効性と安全性.口頭発表（一般）
- 第38回日本造血幹細胞移植学会総会, 2015年03月, 日本語, 日本造血細胞移植学会, 名古屋, 国内会議骨髄非破壊的造血幹細胞移植後の非感染性心内膜炎口頭発表（一般）
- 第37回日本造血細胞移植学会総会, 2015年03月, 英語, 日本造血細胞移植学会, 神戸, 国内会議骨髄非破壊的造血幹細胞移植後の非感染性心内膜炎口頭発表（一般）
- 第54回 神戸血液病研究会, 2015年02月, 日本語, 神戸血液病研究会, 神戸, 国内会議急性骨髄性白血病に対して同種骨髄移植後にCandida Parapsilosis による横紋筋融解症を呈した1例口頭発表（一般）
- 56th Meeting of the American Society of Hematology, 2014年12月, 英語, American Society of Hematology, サンフランシスコ, 国際会議Efficacy of the Two-Dose Influenza Vaccine in Cancer Patients Receiving Chemotherapy: A Prospective Study.ポスター発表
- 第76回日本血液学会総会, 2014年11月, 英語, 日本血液学会, 大阪, 国内会議Rapid recovery of lymphocyte counts after stopping MTX treatment might predict following regression of MTX-LPD.ポスター発表
- 第76回日本血液学会学術集会, 2014年10月, 日本語, 日本血液学会, 大阪, 国内会議肺、大腸重複癌に合併した自己免疫性溶血性貧血における自己抗体の標的分子の同定口頭発表（一般）
- 第76回日本血液学会学術集会, 2014年10月, 英語, 日本血液学会, 大阪, 国内会議MYC amplification in the form of double minute chromosomes in two cases of acute myeloid leukemia.ポスター発表
- 第76回日本血液学会学術集会, 2014年10月, 英語, 日本血液学会, 大阪, 国内会議A case of spontaneous hemophilia B diagnoses in adulthoodポスター発表
- 第201回日本内科学会近畿地方会, 2014年09月, 日本語, 日本内科学会, 京都, 国内会議骨髄異形成症候群に結核性多発膿瘍を併発した1例。口頭発表（一般）
- 第73回日本癌学会学術総会, 2014年09月, 日本語, 日本癌学会, 横浜, 国内会議NK細胞浸潤がヒト乳がん異種移植マウスの腫瘍増殖に与える影響ポスター発表
- 第73回日本癌学会学術総会, 2014年09月, 英語, 日本癌学会, 横浜, 国内会議Effect of natural killer cell infiltration on the growth of the mouse xenografts tumors of human breast cancers.ポスター発表
- 第12回日本臨床腫瘍学会学術集会, 2014年07月, 日本語, 日本臨床腫瘍学会, 福岡, 国内会議気道狭窄を伴う異なる頸部悪性腫瘍の2例ポスター発表
- 第307回公益社団法人日本医学放射線学会関西地方会(第379回レントゲンアーベント), 2014年06月, 日本語, 公益社団法人日本医学放射線学会関西地方会, 大阪, 国内会議当院におけるゼヴァリンの初期経験口頭発表（一般）
- 第64回日本皮膚科学会中部支部学術大会, 2013年11月, 日本語, 日本皮膚科学会中部支部, 名古屋, 国内会議多発筋炎の加療中に生じたMycobacterium haemophilum感染症の1例口頭発表（一般）
- 第75回日本血液学会学術集会, 2013年10月, 日本語, 日本血液学会, 札幌, 国内会議Results of a retrospective study about MTX-LPD and a puestionnaire 'How I treat MTX-LPD'ポスター発表
- 第75回日本血液学会学術集会, 2013年10月, 日本語, 日本血液学会, 札幌, 国内会議Extramedullary T-lymphoid crisis of ETV6/ABL1-positive myeloproliferative neoplasm with t(7;14)ポスター発表
- 第75回日本血液学会学術集会, 2013年10月, 英語, 日本血液学会, 札幌, 国内会議A case of primary cardiac intermediate Burkitt / Diffuse large B cell lymphomaポスター発表
- 第37回日本頭頸部癌学会, 2013年06月, 日本語, 日本頭頸部癌学会, 新宿、東京（京王プラザホテル）, 国内会議鼻腔原発NK／T細胞リンパ腫に対する放射線治療経験ポスター発表
- 第37回日本頭頸部癌学会, 2013年06月, 日本語, 日本頭頸部癌学会, 新宿、東京（京王プラザホテル）, 国内会議甲状腺原発MALTリンパ腫の治療経験ポスター発表
- 日本放射線腫瘍学会第25回学術大会, 2012年11月, 日本語, 日本放射線腫瘍学会, 東京（東京国際フォーラム）, 国内会議鼻腔原発NK/T 細胞リンパ腫に対する放射線治療経験ポスター発表
- 第74回日本血液学会学術集会, 2012年10月, 日本語, 日本血液学会, 京都, 国内会議A novel TRB@/NOTCH1 fusion gene in T-cell lymphoblastic lymphoma with t(7;9)(q34;q34)ポスター発表
- 第10回日本臨床腫瘍学会学術集会, 2012年07月, 日本語, 日本臨床腫瘍学会, 大阪, cancer related VTEの現状, 国内会議当科における悪性腫瘍に伴う静脈血栓塞栓症（VTE）の検討ポスター発表
- 第10回日本臨床腫瘍学会学術集会, 2012年07月, 日本語, 日本臨床腫瘍学会, 大阪, 当科においける静脈血栓塞栓症(VTE) 症例の検討, 国内会議当科においける静脈血栓塞栓症(VTE) 症例の検討ポスター発表
- 第10回日本臨床腫瘍学会学術集会, 2012年07月, 日本語, 日本臨床腫瘍学会, 大阪, 切除不能神経内分泌腫瘍に対するダカルバジン単剤療法：後方視的解析, 国内会議切除不能神経内分泌腫瘍に対するダカルバジン単剤療法：後方視的解析ポスター発表
- 第74回日本血液学会学術集会, 2012年06月, 英語, 日本血液学会, 京都, 国内会議Secondary Phiradelphia-positive mixed-phenotype acute leukemia after adjuvant chemotherapy with S-1.ポスター発表
- 第109回日本内科学会講演会, 2012年04月, 日本語, 日本内科学会, 京都, 切除不能高分化神経内分泌腫瘍に対するダカルバジン療法, 国内会議切除不能高分化神経内分泌腫瘍に対するダカルバジン療法ポスター発表
- 第70回日本医学放射線学会総会, 2011年05月, 日本語, 日本医学放射線学会, 震災の影響によりWEB開催, 国内会議鼻腔NK/T細胞性リンパ腫に対する放射線治療の経験口頭発表（一般）
- 第33回日本造血細胞移植学会総会, 2011年03月, 日本語, 日本造血細胞移植学会, 松山, 国内会議臍帯血移植前にﾎﾞﾘｺﾅｿﾞｰﾙ水晶体内投与が有効であった真菌性眼内炎ポスター発表
- 第33回日本造血細胞移植学会総会, 2011年03月, 日本語, 日本造血細胞移植学会, 松山, 国内会議急性GVHD予防薬ﾐｺﾌｪﾉｰﾙ酸ﾓﾌｪﾁﾙ（MMF)使用下における移植後G-CSF至適投与量の検討ポスター発表
- 第94回近畿血液学地方会, 2010年11月, 日本語, 近畿血液学地方会, 大津, 国内会議MTX関連リンパ腫の2例口頭発表（一般）
- 第40回日本腎臓学会西部学術大会, 2010年10月, 日本語, 広島, 国内会議両腎への形質細胞腫侵潤により腎機能低下に認めた一例ポスター発表
- 第72回日本血液学会総会, 2010年09月, 日本語, 日本血液学会, 横浜, 国内会議Therapy-related pure erythroid leukemia with hemophagocytic syndromeポスター発表
- 第72回日本血液学会総会, 2010年09月, 日本語, 日本血液学会, 横浜, 国内会議Efficacy and safety of a new salvage protocol, CAG-G-GO (GO following CAG and G-CSF), for refractory or relapsed AML口頭発表（一般）
- 第72回日本血液学会総会, 2010年09月, 日本語, 日本血液学会, 横浜, 国内会議A novel dicentric chromosome, dic(9;9)(p12;q34), in follicular lymphoma withaut t(14;18)ポスター発表
- 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2023年04月01日 - 2026年03月31日革新的新技術を用いた大腸がん患者の早期発見につながるリキッドバイオプシーの確立
- 学術研究助成基金助成金／基盤研究(C), 2015年04月 - 2018年03月, 研究代表者競争的資金
- 科学研究費補助金／基盤研究(C), 2012年04月 - 2015年03月, 研究代表者競争的資金
- 日本学術振興会, 科学研究費助成事業 萌芽研究, 萌芽研究, 和歌山県立医科大学, 2006年 - 2007年造血幹細胞と幹細胞ニッチの相互作用における軸索ガイダンス分子の機能の解明軸索ガイダンス分子の骨髄内における詳細な発現解析を行った。どの軸索ガイダンス分子が骨髄内のどの細胞に発現しているのかを知るためにin situ hybridization法、免疫組織化学ならびにAP in situ法(affinity probe in situ法)を用い、kit(造血幹細胞)、osteocalcin(骨芽細胞)などの各細胞のマーカーと二重染色を行い、各分子の発現分布を明らかにした。これらによりいくつかの分子の骨髄細胞上における特徴的発現様式を認めた。したがって、これらの分子は機能解析実験の候補蛋白となると考え、次の機能実験を行った。 in vivo機能アッセイによる軸索ガイダンス分子機能のスクリーニング 造血幹細胞-ニッチ間の接着を司る分子は造血幹細胞の細胞周期を休止させ外的ストレスから幹細胞を守る働きを持つことが示唆されてきた。造血幹細胞に発現の見られるガイダンス分子について、マウスに外的ストレスを加え、ニッチに接着して残存した造血幹細胞に当該ガイダンス分子が発現しているか(当該ガイダンス分子によって残存できた可能性があるのか)を見た。また、当該分子が細胞周期を遅くするのに役立っているかどうかのスクリーニングとして、BrdU long term retaining cellsと当該分子の二重染色を行った。 in vitro機能アッセイによる軸索ガイダンス分子機能の再構成 collagen gel assayはgel内にガイダンス分子の濃度勾配を再現しておき、この濃度勾配中に調べる細胞を置いて細胞濃度勾配に誘引されて移動するか、濃度勾配に反発して逆向きに移動するかを見るものである。造血幹細胞を当該ガイダンス分子の濃度勾配中において誘引ないしは反発を観察することによりニッチからの遊走やニッチに向かうhomingの機序をin vitroで検討した。